

10/556, 230 12/21/2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1			Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 15		CAOLD to be discontinued on December 31, 2008
NEWS 3	OCT 07		EPFULL enhanced with full implementation of EPC2000
NEWS 4	OCT 07		Multiple databases enhanced for more flexible patent number searching
NEWS 5	OCT 22		Current-awareness alert (SDI) setup and editing enhanced
NEWS 6	OCT 22		WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7	OCT 24		CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8	NOV 21		CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9	NOV 26		MARPAT enhanced with FSORT command
NEWS 10	NOV 26		MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11	NOV 26		CHEMSAFE now available on STN Easy
NEWS 12	NOV 26		Two new SET commands increase convenience of STN searching
NEWS 13	DEC 01		ChemPort single article sales feature unavailable
NEWS 14	DEC 12		GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 15	DEC 17		Fifty-one pharmaceutical ingredients added to PS
NEWS EXPRESS	JUNE 27 08		CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

10/556, 230 12/21/2008

FILE 'REGISTRY' ENTERED AT 18:38:05 ON 21 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2008 HIGHEST RN 1087349-26-5
DICTIONARY FILE UPDATES: 19 DEC 2008 HIGHEST RN 1087349-26-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\105562304.str



```

chain nodes :
10 11 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
8-10 10-11 11-12 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
   16-17
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 10-11 18-19 18-20
exact bonds :
11-12

```


10/556,230 12/21/2008

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 18:38:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1139 TO ITERATE

100.0% PROCESSED 1139 ITERATIONS 29 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 20756 TO 24804
PROJECTED ANSWERS: 257 TO 903



L2 29 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 18:38:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22324 TO ITERATE

100.0% PROCESSED 22324 ITERATIONS 516 ANSWERS
SEARCH TIME: 00.00.01

L3 516 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\105562306.str




chain nodes :
10 11 18 19 20 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
8-10 10-11 11-12 18-19 18-20 20-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
5-7 6-9 7-8 8-9 8-10 10-11 18-19 18-20 20-23 23-24
exact bonds :
11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 12 :

G1:A,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom 23:CLASS 24:CLASS

L4 STRUCTURE UPLOADED

=> D
L4 HAS NO ANSWERS
L4 STR



G1 A, Hy

Structure attributes must be viewed using STN Express query preparation.

=> S L4
 SAMPLE SEARCH INITIATED 18:44:28 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 787 TO ITERATE

100.0% PROCESSED 787 ITERATIONS 29 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 14057 TO 17423
 PROJECTED ANSWERS: 257 TO 903

L5 29 SEA SSS SAM L4

=> S L5 FULL
 FULL SEARCH INITIATED 18:44:42 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 15746 TO ITERATE

100.0% PROCESSED 15746 ITERATIONS 508 ANSWERS
 SEARCH TIME: 00.00.01

L6 508 SEA SSS FUL L4

=> FILE CAPLUS
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 360.86 361.07

FILE 'CAPLUS' ENTERED AT 18:44:48 ON 21 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

10/556,230 12/21/2008

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2008 VOL 149 ISS 26
FILE LAST UPDATED: 19 Dec 2008 (20081219/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolICY.html>


=> S L6
L7 13 L6

=> D IBIB ABS HITSTR TOT

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:727286 CAPLUS
 DOCUMENT NUMBER: 149:215094
 TITLE: Discovery of potent, orally active benzimidazole glucagon receptor antagonists
 AUTHOR(S): Kim, Ronald M.; Chang, Jiang; Lins, Ashley R.; Brady, Ed; Candelore, Mari R.; Dallas-Yang, Qing; Ding, Victor; Dragovic, Jasminka; Iliff, Susan; Jiang, Guoqiang; Mock, Steven; Qureshi, Sajjad; Saperstein, Richard; Szalkowski, Deborah; Tamvakopoulos, Constantine; Tota, Laurie; Wright, Michael; Yang, Xiaodong; Tata, James R.; Chapman, Kevin; Zhang, Bei B.; Parmee, Emma R.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(13), 3701-3705
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The discovery and optimization of potent and selective aminobenzimidazole glucagon receptor antagonists are described. One compound possessing moderate pharmacokinetic properties in multiple preclin. species was orally efficacious at inhibiting glucagon-mediated glucose excursion in transgenic mice expressing the human glucagon receptor, and in rhesus monkeys. The compound also significantly lowered glucose levels in a murine model of diabetes.
 IT 798534-45-9 798534-79-9
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazole glucagon receptor antagonists)
 RN 798534-45-9 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798534-79-9 CAPLUS
 CN Benzamide, 4-[[[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



IT 1042741-30-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (benzimidazole glucagon receptor antagonists)
 RN 1042741-30-9 CAPLUS
 CN Benzamide, 4-[[1-(1,5-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-


L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (CA INDEX NAME)

Relative stereochemistry.




IT 798533-50-3 798533-51-4 798533-53-6
 798533-54-7 798533-58-1 798533-59-2
 798533-60-5 798533-61-6 798533-62-7
 798533-66-3 798533-70-7 798533-73-0
 798533-96-7 798534-22-2 798534-46-0
 798534-49-3 798534-68-6 798534-93-7
 798535-00-9 798535-12-3 798535-33-8
 798535-42-9 798535-48-5 798535-73-6
 798535-86-1 1042741-35-4 1042741-36-5
 1042741-38-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazole glucagon receptor antagonists)
 RN 798533-50-3 CAPLUS
 CN β -Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798533-51-4 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-53-6 CAPLUS
 CN Propanoic acid, 3-[[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-54-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-59-1 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-59-2 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-60-5 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-61-6 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-62-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-66-1 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-70-7 CAPLUS
 CN Benzamide, 4-[[[1-cyclopentyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-73-0 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(phenylmethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-96-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-22-2 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-46-0 CAPLUS
 CN Benzamide, 4-[[[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-49-3 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1,5,6-trimethyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-68-6 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-93-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-methoxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-00-9 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-12-3 CAPLUS
 CN Benzamide, 4-[[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.




RN 798535-33-8 CAPLUS
 CN Benzamide, 4-[[[3-chloro-4-(4-chlorophenoxy)phenyl](6-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798535-42-9 CAPLUS
 CN Benzamide, 4-[[[4-cyclohexylphenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-49-5 CAPLUS
 CN Benzamide, 4-[[[(1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-73-6 CAPLUS
 CN Benzamide, 4-[[[5-bromo-1-methyl-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-86-1 CAPLUS
 CN Benzamide, 4-[[[4-(1,1-dimethylethyl)phenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 1042741-35-4 CAPLUS
 CN Benzamide, 4-[[[cis-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 1042741-36-5 CAPLUS
 CN Benzamide, 4-[[[methyl(1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 1042741-38-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-fluoro-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors

INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierre; Plas, Pascale

PATENT ASSIGNEE(S): Societe des Conseils de Recherches et d'Applications (S.C.R.A.S.), Fr

SOURCE: U.S. Pat. Appl. Publ., 204pp., Cont.-in-part of U.S. Ser. No. 504,033.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080139619	A1	20080612	US 2008-12184	20080131
WO 2004075823	A2	20040910	WO 2004-FR418	20040225
WO 2004075823	A3	20041007		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LZ, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CL, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, EO, GW, ML, MR, NE, SN, TD, TG			
US 20050065179	A1	20050324	US 2004-915920	20040811
US 20050267147	A1	20051201	US 2004-504033	20040928
US 7355052	B2	20080408		
	PRIORITY APPLN. INFO.:		WO 2004-FR418	W 20040225
			US 2004-915920	A3 20040811
			US 2004-504033	A2 20040928
			FR 2003-2320	A 20030226
			US 2003-504033	A2 20030920

OTHER SOURCE(S): MARPAT 149:53994
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH₂, CO, (un)substituted COCH₂; X = CH, N; R₁, R₂ = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R₁R₂ = (un)substituted hetero(bi)cycloalkyl; R₃ = alkyl, alkoxy,

L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
alkylthio, heteroaryl, (un)substituted hetero/cycloalkyl, aryl, etc.; R₄ = (CH₂)_sR₅; R₅ = heterocycloalkyl, heteroaryl, etc.; s = 0-6] were prep'd. as melanocortin (MC), in particular MC4, receptor modulators (no data given).

For example, II was prep'd., in 2 steps, by amination of 3-fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (prepn. given) with 3-(piperidino)propylamine in CH₃Cl at reflux, followed by one-step hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compns. contg. compds. I.



IT 848577-11-7P 848577-17-3P 848577-39-9P
848577-48-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

for (preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)


RN 848577-11-7 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 2-[[[4-


[(methylamino)carbonyl]phenyl]methyl]amino]-N,N-bis(3-methylbutyl)-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 848577-17-3 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N,N-dibutyl-2-[[[4-[(methylamino)carbonyl]phenyl]methyl]amino]-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 848577-39-9 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[[[4-[(methylamino)carbonyl]phenyl]methyl]amino]-N,N-bis(3-methylbutyl)-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 848577-48-0 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N,N-dibutyl-2-[[[4-[(methylamino)carbonyl]phenyl]methyl]amino]-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:863150 CAPLUS
 DOCUMENT NUMBER: 147:422126
 TITLE: Colorimetric anion chemosensor based on 2-aminobenzimidazole: Naked-eye detection of biologically important anions
 AUTHOR(S): Moon, Kyung Soo; Singh, Narinder; Lee, Gang Woo; Jang, Doo Ok
 CORPORATE SOURCE: Department of Chemistry, Yonsei University, Wonju, 220-710, S. Korea
 SOURCE: Tetrahedron (2007), 63(37), 9106-9111
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:422126
 AB The authors synthesized a novel colorimetric anion chemosensor bearing benzimidazole motifs as recognition sites in the pods of the receptor. The addition of tetrabutylammonium salts of F- or AcO- to the solution of receptor caused dramatic color changes from colorless to yellow, which was clearly visible to the naked eye. The receptor showed no significant changes on addition of other anions such as Cl-, Br-, I-, NO3-, and H2PO4-
 IT 951305-08-1P RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (colorimetric anion chemosensor based on 2-aminobenzimidazole: naked-eye detection of biol. important anions)
 RN 951305-08-1 CAPLUS
 CN 1,3-Benzenedicarboxamide, N1,N3-bis(6-nitro-1H-benzimidazol-2-yl)- (CA INDEX NAME)




IT 57489-96-0P, N,N'-Bis(benzimidazol-2-yl)isophthalamide
 RL: SPN (Synthetic preparation); PREP (Preparation) (colorimetric anion chemosensor based on 2-aminobenzimidazole: naked-eye detection of biol. important anions)
 RN 57489-96-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N1,N3-bis(1H-benzimidazol-2-yl)- (CA INDEX NAME)

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:593083 CAPLUS
 DOCUMENT NUMBER: 148:91590
 TITLE: Perchlorate selective sensor based on a newly synthesized hydrogen-bonding diamide receptor
 AUTHOR(S): Jain, Ajay Kumar; Raisoni, Jitendra; Kumar, Ravindra; Jain, Shalabh
 CORPORATE SOURCE: Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, India
 SOURCE: International Journal of Environmental Analytical Chemistry (2007), 87(8), 553-563
 PUBLISHER: Taylor & Francis Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The ionophore, N1,N3-di(1H-benzimidazol-2-yl)isophthalamide receptor (I) was synthesized and characterized by UV, IR, and CHN anal. Polyvinyl chloride (PVC)-based membranes of (I) were prepared and explored as ClO4- selective sensors. The effect of various plasticizers, viz. tris(2-ethylhexyl) phosphate (TEHP), di-Bu phosphate (DBP), dioctyl phosphate (DOP), di-Et phosphate (DEP), tricresyl phosphate (TCP), and a cation excluder, tridodecylmethylammonium chloride (TDDMACl), was studied in detail, and an improved performance was observed in several instances. Optimum performance was observed with the membrane having (I)-PVC-TDDMACl-DBP in the ratio 1:120:1:200 (mg). The sensor works satisfactorily in the concentration range 1.8 × 10-5 to 1.0 × 10-1 M with near-Nernstian compliance (52.0 mV per decade of activity) between pH 4.0 and 10.0 with a fast response time of .apprx.12 s. The potentiometric selectivity coefficient values as determined by the fixed interference method indicate a selective response for ClO4- in the presence of interfering ions. The sensor exhibits adequate shelf-life (.apprx.2 mo) with a good reproducibility (SD ± 0.4 mV).
 IT 57489-96-0P RL: ARG (Analytical reagent use); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses) (perchlorate selective sensor based on hydrogen-bonding diamide receptor)
 RN 57489-96-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N1,N3-bis(1H-benzimidazol-2-yl)- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 200715632 CAPLUS
 DOCUMENT NUMBER: 146:267697
 TITLE: Cloning and expression of canine glucagon receptor
 and its use to evaluate glucagon receptor antagonists in
 vitro and in vivo
 AUTHOR(S): Yang, Xiaodong; Yates, Marla L.; Candelore, Mari R.;
 Feeney, William; Hora, Don; Kim, Ron M.; Parmee, Emma
 R.; Berger, Joel P.; Zhang, Bei B.; Qureshi, Sajjad
 A.
 CORPORATE SOURCE: Department of Metabolic Disorder-Molecular
 Endocrinology, Merck Research Laboratories, Rahway,
 NJ, 07065, USA
 SOURCE: European Journal of Pharmacology (2007), 555(1), 8-16
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Glucose homeostasis is maintained by the combined actions of insulin and glucagon. Hyperglucagonemia and/or elevation of glucagon/insulin ratio have been reported in diabetic patients and in animal models of diabetes. Therefore, antagonizing glucagon receptor function has long been considered a useful approach to lower hyperglycemia. Dogs serve as an excellent model for studying glycemic control and various aspects of glucagon biof. In vivo, however, the amino acid sequence of the dog glucagon receptor has not been reported. To better understand the pharmacol. of the dog glucagon receptor and to characterize glucagon receptor antagonists, we cloned a cDNA corresponding to the glucagon receptor from dog liver RNA. The dog glucagon receptor shares a significant (> 75%) homol. at both nucleotide and amino acid levels with the glucagon receptor from human, monkey, mouse, and rat. The protein is highly conserved among all species in areas corresponding to the 7 trans-membrane domains. However, it shows significant divergence at the carboxy terminus such that the receptor from dog has the longest cytoplasmic tail among all species examined. When expressed in Chinese hamster ovary cells, the dog glucagon receptor bound [¹²⁵I]Glucagon with
 a Kd of 477 ± 106 pM. Glucagon stimulated the rise of intracellular cAMP levels in these cells with an EC₅₀ of 9.6 ± 1.7 nM and such effects could be blocked by known peptidyl and non-peptidyl small mol. antagonists. In addition we show that a small mol. glucagon receptor antagonist with significant activity in cell based assays also blocked
 the ability of glucagon to induce elevation in blood glucose in beagle dogs. These data demonstrate that the cloned cDNA encodes a functional dog glucagon receptor. The availability of the dog cDNA will facilitate the understanding of glucagon pharmacol. and aid in the characterization of novel glucagon antagonists that may serve as anti-hyperglycemic treatment for type 2 diabetes mellitus.
 IT 798538-22-4
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (glucagon receptor antagonist; cloning, protein and cDNA sequences and expression of canine glucagon receptor and its use to evaluate
 glucagon

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005259680 CAPLUS
 DOCUMENT NUMBER: 142:336356
 TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors
 INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierrie; Plas, Pascale
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 213 pp., Cont.-in-part of U.S. Ser. No. 504,033.
 SOURCE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050065179	A1	20050324	US 2004-915920	20040811
FR 2851563	A1	20040827	FR 2003-2320	20030226
FR 2851563	B1	20050422		
WO 2004075823	A2	20040910	WO 2004-FR418	20040225
WO 2004075823	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GN, HR, HO, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, BW, GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20080139619	A1	20080612	US 2008-12184	20080131
PRIORITY APPN. INFO.:			US 2003-2320	A 20030226
			US 2003-504033	A2 20030920
			WO 2004-FR418	W 20040225
			US 2004-915920	A3 20040811
			US 2004-504033	A2 20040928


OTHER SOURCE(S): CASREACT 142:336356; MARPAT 142:336356
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH₂, CO, (un)substituted COCH₂; X = CH, N; R₁, R₂ = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R₁R₂ = (un)substituted hetero(bi)cycloalkyl; R₃ = alkyl, alkoxy, alkylthio, heteroaryl, (un)substituted hetero/cycloalkyl, aryl, etc.; R₄ = (CH₂)_sR₅; R₅ = heterocycloalkyl, heteroaryl, etc.; s = 0-6] were prepared as

Saeed

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 receptor antagonists in vitro and in vivo
 RN 798538-22-4 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 melanocortin (MC), in particular MC4, receptor modulators (no data given)



For example, II was prep., in 2 steps, by amination of 3-Fluoro-N,N-bis(3-methylbutyl)nitrobenzamide (prep. given) with 3-(piperidino)propylamine in CH₃CN at reflux, followed by one-step hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are included such as pain, inflammatory conditions, etc.

IT 848577-11-7P 848577-17-3P 848577-39-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzimidazoles and imidazopyridines having affinity

for melanocortin (MC), in particular MC4, receptors)
 RN 848577-11-7 CAPLUS
 CN 1H-Benzimidazole-6-carboxamide, 2-[[[4-(
 [methylamino]carbonyl]phenyl)methyl]amino]-N,N-bis(3-methylbutyl)-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 848577-17-3 CAPLUS
 CN 1H-Benzimidazole-6-carboxamide, N,N-dibutyl-2-[[[4-(
 [methylamino]carbonyl]phenyl)methyl]amino]-1-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 848577-39-9 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[[[4-
{(methylamino)carbonyl]phenyl}methyl]amino]-N,N-bis(3-methylbutyl)-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 848577-48-0 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, N,N-dibutyl-2-[[[4-
{(methylamino)carbonyl]phenyl}methyl]amino]-1-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 2004:1015854 CAPLUS
DOCUMENT NUMBER: 142:6533
TITLE: Benzimidazoles, compositions containing such compounds, methods of use, and their preparation
INVENTOR(S): Parmee, Emma R.; Kim, Ronald M.; Liang, Rui; Chang, Jiang; Rouse, Elizabeth Ashley; Chapman, Kevin T.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004100875	A2	20041125	WO 2004-US13874	20040505
WO 2004100875	A3	20050317		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BH, GI, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AZ, BX, KG, KZ, MD, RO, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, CR, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004238240	A1	20041125	AU 2004-238240	20040505
CA 2524436	A1	20041125	CA 2004-2524436	20040505
EP 1626717	A2	20060222	EP 2004-751318	20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PI, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1784226	A	20060607	CN 2004-80012489	20040505
JP 2006528687	T	20061221	JP 2006-532564	20040505
IN 2005DN04615	A	20071207	IN 2005-DN4615	20051010
US 20070093544	A1	20070426	US 2005-556230	20051109
PRIORITY APPLN. INFO.:			US 2003-469332P	P 20030509
			US 2003-467951P	P 20030505
			WO 2004-US13874	W 20040505

OTHER SOURCE(S): MARPAT 142:6533
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to substituted benzimidazoles I [wherein A = C(:O)N(R5)(CH2)n(CR6R7)m; R1 = H, OH, halo, (un)substituted alk(en)ynyl],

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

than 0, Z = CO2H and derivs., 5-tetrazolyl, 5-(2-oxo-1,3,4-oxadiazolyl), and when both m and n are 0, Z = 5-tetrazolyl, 5-(2-oxo-1,3,4-oxadiazolyl)], their pharmaceutically acceptable salts and solvates, compns. contg. such compds. and methods of treatment. I are glucagon receptor antagonists and

thus are useful for treating, preventing or delaying the onset of type II diabetes mellitus (no data). For example, II was prep'd. in 4 steps by cyclization of N-methyl-1,2-phenylene diamine with thiophosgene and 2,5-dichloroaniline to benzimidazole III, amination of Et 4-(bromomethyl)benzoate with III, ester hydrolysis, and reaction of the acid with 1H-tetrazol-5-amino monohydrate.

IT 798533-46-7P, 4-[[1H-Benzimidazol-2-yl]-trans-4-tert-butylycyclohexyl]amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-47-8P 798533-48-9P,
4-[[1H-Benzimidazol-2-yl]-trans-4-tert-butylycyclohexyl]amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-50-3P, N-[4-[[trans-4-tert-butylycyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine
798533-51-4P, 4-[[trans-4-tert-butylycyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-52-5P, Methyl (2R)-3-[[4-[[trans-4-tert-butylycyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxypropanoate 798533-53-6P,
(2R)-3-[[4-[[trans-4-tert-butylycyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-54-7P, 4-[[trans-4-tert-butylycyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)methylbenzamide
798533-55-8P, 4-[[trans-4-tert-butylycyclohexyl](1-(2-hydroxyethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-56-9P,
4-[[6-(Allyloxy)-1-methyl-1H-benzimidazol-2-yl](4-tert-butylycyclohexyl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-57-0P, 4-[[trans-4-tert-butylycyclohexyl](6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-58-1P, 4-[[trans-4-tert-butylycyclohexyl](1-methyl-6-

propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-59-2P, 4-[[trans-4-tert-butylycyclohexyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-60-5P, 4-[[trans-4-tert-butylycyclohexyl](5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-61-6P, 4-[[trans-4-tert-butylycyclohexyl](5-benzyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-62-7P, 4-[[trans-4-tert-butylycyclohexyl](1-(1H-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-63-8P 798533-64-9P,

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

4-[[trans-4-tert-butylycyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)methylbenzamide
798533-65-0P, (2R)-3-[[4-[[1-Ethyl-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-66-1P, 4-[[trans-4-tert-butylycyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-67-2P, 798533-68-3P,
4-[[trans-4-tert-butylycyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-69-4P, (2R)-3-[[4-[[1-Propyl-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-70-7P, 4-[[trans-4-tert-butylycyclohexyl](1-cyclopentyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-71-8P 798533-72-9P,
(2R)-3-[[4-[[1-Cyclopentyl]-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-73-0P, 4-[[trans-4-tert-butylycyclohexyl](1-benzyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-74-1P, N-[4-[[trans-4-tert-butylycyclohexyl](1-benzyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine
798533-75-2P, 4-[[trans-4-tert-butylycyclohexyl](1-benzyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-76-3P, (2R)-3-[[4-[[1-Benzyl-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-77-4P, 4-[[trans-4-tert-butylycyclohexyl](1-isobutyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-78-5P, N-[4-[[trans-4-tert-butylycyclohexyl](1-isobutyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine
798533-79-6P, 4-[[trans-4-tert-butylycyclohexyl](1-isobutyl-1H-benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-yl]benzamide
798533-80-9P, N-[4-[[trans-4-tert-butylycyclohexyl](1-isobutyl-1H-Benzimidazol-2-yl)amino]methyl]benzoyl]-N-[1H-tetrazol-5-yl]benzamide
798533-81-0P, 4-[[trans-4-tert-butylycyclohexyl](1-(2-fluoroethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide 798533-82-1P,

N-[4-[[trans-4-tert-butylycyclohexyl](1-(2-fluoroethyl)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine 798533-83-2P,
4-[[trans-4-tert-butylycyclohexyl](1-(2-fluoroethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-yl]benzamide
798533-84-3P, (2R)-3-[[4-[[1-(2-fluoroethyl)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-85-4P, 4-[[trans-4-tert-butylycyclohexyl](1-allyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-86-5P, 4-[[trans-4-tert-butylycyclohexyl](1-allyl-1H-benzimidazol-2-yl)amino]methyl]-N-(1H-tetrazol-5-yl)benzamide
798533-87-6P, (2R)-3-[[4-[[1-Allyl-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-88-7P, N-[4-[[trans-4-tert-butylycyclohexyl](1-(2-hydroxyethyl)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine
798533-89-8P, (2R)-3-[[4-[[1-(2-Hydroxyethyl)-1H-Benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-90-1P, 4-[[trans-4-tert-butylycyclohexyl](1-(3-hydroxypropyl)-1H-benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-yl]benzamide
798533-91-2P, (2R)-3-[[4-[[1-Allyl-1H-Benzimidazol-2-yl](trans-4-tert-butylycyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
798533-92-3P, 4-[[trans-4-tert-butylycyclohexyl](1-(2-dimethylamino)ethyl)-1H-benzimidazol-2-yl]amino]-N-(1H-tetrazol-5-yl)benzamide

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 yl)benzamide 798533-93-4P,
 4-[(trans-4-*tert*-Butylcyclohexyl)[1-(4-trifluoromethoxybenzyl)-1H-benimidazol-2-yl]amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798533-94-5P, N-[4-[(trans-4-*tert*-Butylcyclohexyl)[1-(4-trifluoromethoxybenzyl)-1H-benimidazol-2-yl]amino]methyl]benzoyl]- β -alanine 798533-95-6P, (2R)-3-[4-[(1-[4-(4-Trifluoromethoxybenzyl)-1H-Benimidazol-2-yl](trans-4-*tert*-butylcyclohexyl)amino)methyl]benzoyl]amino]-2-hydroxypropanoic acid 798533-96-7P, 4-[(trans-4-*tert*-Butylcyclohexyl)(1-phenyl-1H-benimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide 798533-97-8P, N-[4-[(trans-4-*tert*-Butylcyclohexyl)(1-phenyl-1H-benimidazol-2-yl)amino]methyl]benzoyl]- β -alanine 798533-98-9P, 4-[(trans-4-*tert*-Butylcyclohexyl)(1-phenyl-1H-benimidazol-2-yl)amino]methyl-N-[1H-tetrazol-5-yl]methyl]benzamide 798533-99-0P, (2R)-3-[4-[(1-Phenyl-1H-Benimidazol-2-yl)(trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-00-6P, 4-[(trans-4-*tert*-Butylcyclohexyl)[1-(4-chlorobenzyl)-1H-benimidazol-2-yl]amino]methyl-N-(1H-tetrazol-5-yl)benzamide 798534-02-8P, (2R)-3-[4-[(1-[4-Chlorobenzyl)-1H-Benimidazol-2-yl](trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-03-9P, 4-[(trans-4-*tert*-Butylcyclohexyl)[1-(3-chlorobenzyl)-1H-benimidazol-2-yl]amino]methyl-N-(1H-tetrazol-5-yl)benzamide 798534-04-0P,

N-[4-[(4-[(trans-4-*tert*-Butylcyclohexyl)[1-(3-chlorobenzyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]-*β*-alanine 798534-05-1P,
 (2R)-3-[4-[(1-[3-chlorobenzyl)-1H-Benzimidazol-2-yl](trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl-2-hydroxypropanoic acid 798534-06-2P, 4-[(trans-4-*tert*-Butylcyclohexyl)[1-(2,4-dichlorobenzyl)-1H-benzimidazol-2-yl]amino]methyl-3-*N*-(1H-tetrazol-5-yl)benzamide 798534-07-3P,
 N-[4-[(trans-4-*tert*-Butylcyclohexyl)[1-(2,4-dichlorobenzyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]-*β*-alanine 798534-08-4P, (2R)-3-[4-[(1-[2,4-Dichlorobenzyl)-1H-Benzimidazol-2-yl](trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-09-5P

4-[(trans-4-tert-Butylcyclohexyl)[1-(3,4-dichlorobenzyl)-1H-benzimidazol-2-yl]amino]methyl]-N-[1H-tetrazol-5-yl]benzamide 798534-10-8P
 798534-11-9P, (2R)-3-[(4-[(1-[3,4-Dichlorobenzyl]-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)benzoyl]amino]-2-hydroxypropanoic acid 798534-12-0P,
 4-[(trans-4-tert-Butylcyclohexyl)[1-(4-cyanobenzyl)-1H-benzimidazol-2-vinyl]amino]methyl-N-[1H-tetrazol-5-yl]benzamide 798534-13-1P.

N-[4-[(trans-4-*tert*-Butylcyclohexyl)[1-(4-cyanobenzyl)-1H-benzimidazol-1-yl]amino]methyl]benzoyl- β -alanine 798534-14-2P,
 (2R)-3-[(4-[(1-(4-Cyano benzyl)-1H-Benzimidazol-2-yl)(trans-4-*tert*-butylcyclohexyl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid 798534-15-3P, 4-[(trans-4-*tert*-Butylcyclohexyl)[1-(4-nitrobenzyl)-1H-benzimidazol-2-yl]amino]methyl-N-(1H-tetrazol-5-yl)benzamide 798534-16-4P 798534-17-5P,
 (2R)-3-[(4-[(1-(4-Nitrobenzyl)-1H-Benzimidazol-2-yl)(trans-4-*tert*-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 798534-43-7F, (2R)-3-[(4-[(1,6-Dimethyl-1H-Benzimidazol-2-yl)-(trans-4-tert-Butylcyclohexyl)amino]methyl)benzoyl]amino]-2-hydroxypropanoic acid 798534-44-8F, N-[(4-[(trans-4-tert-Butylcyclohexyl)(1-methyl-5-trifluoromethyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]- β -alanine 798534-45-9F, 4-[(trans-4-tert-Butylcyclohexyl)(1-methyl-5-trifluoromethyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide 798534-46-0P,

4-[(trans-4-tert-Butylcyclohexyl)(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)amino[methyl]-N-(1H-tetrazol-5-yl)benzamide 798534-47-1P,
 N-[4-[(trans-4-tert-Butylcyclohexyl)(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)amino[methyl]benzoyl]- β -alanine
 798534-48-2P, (2R)-3-[4-[(5,6-dichloro-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-49-3P,
 4-[(trans-4-tert-Butylcyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino[methyl]-N-(1H-tetrazol-5-yl)benzamide 798534-50-6P,
 N-[4-[(trans-4-tert-Butylcyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino[methyl]benzoyl]- β -alanine 798534-51-7P,
 (2R)-3-[4-[(1,5,6-Trimethyl-1H-Benzimidazol-2-yl)(trans-4-tert-Butylcyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-52-8P, 4-[(trans-4-tert-Butylcyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino[methyl]-N-(1H-tetrazol-5-yl)methyl]benzamide 798534-53-9P, 4-[(trans-4-tert-Butylcyclohexyl)(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)amino[methyl]-N-(1H-tetrazol-5-yl)benzamide 798534-54-0P, N-[4-[(trans-4-tert-Butylcyclohexyl)(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)amino[methyl]benzoyl]- β -alanine 798534-55-1P, (2R)-3-[4-[(5,6-difluoro-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-56-2P,
 (2R)-3-[4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-57-3P, N-[4-[(trans-4-tert-Butylcyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino[methyl]benzoyl]- β -alanine 798534-58-4P, (2R)-3-[4-[(5-Hydroxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-59-5P,
 4-[(trans-4-tert-Butylcyclohexyl)(5-allyloxy-1-methyl-1H-benzimidazol-2-yl)amino[methyl]-N-(1H-tetrazol-5-yl)benzamide 798534-60-8P,

N-[4-[(trans-4-tert-Butylcyclohexyl)(5-allyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- β -alanine 798534-61-9P,

N-[4-[(trans-4-tert-Butylcyclohexyl)(5-benzyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl-β-alanine 798534-62-0P.

N-[4-[(trans-4-tert-Butylcyclohexyl)(6-allyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl-β-alanine 798534-63-1P.

(2R)-3-[(4-[(6-Allyloxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)benzyl]amino]-2-hydroxypropanoic acid 798534-64-2P, 4-[(trans-4-tert-Butylcyclohexyl)(6-allyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-[(1H-tetrazol-5-yl)methyl]benzyl 798534-65-3P.

N-[4-[(trans-4-tert-Butylcyclohexyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-β-alanine 798534-66-4P, (2R)-4-[(6-Hydroxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-

ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-18-6P, 4-[(*trans*-4-tert-Butylcyclohexyl)[1-(4-methoxybenzyl)-1H-benzimidazol-2-yl]benzamide 798534-19-7P,
 N-[4-[(*trans*-4-tert-Butylcyclohexyl)[1-(4-methoxybenzyl)-1H-benzimidazol-2-yl]β-alanide 798534-20-0P,
 (2R)-3-[(4-[(4-Methoxybenzyl)-1H-benzimidazol-2-yl)(*trans*-4-tert-
 butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-21-1P, N-[4-[(*trans*-4-tert-Butylcyclohexyl)[1-(4-methoxybenzyl)-1H-benzimidazol-2-yl]amino)methyl]benzoyl]β-alanine
 798534-22-2P, 4-[(*trans*-4-tert-Butylcyclohexyl)[1-(4-methoxybenzyl)-1H-benzimidazol-2-yl]amino)methyl]N-(1H-tetrazol-5-yl)benzamide
 798534-23-3P, 4-[(*trans*-4-tert-Butylcyclohexyl)[1-(4-methoxybenzyl)-1H-benzimidazol-2-yl]amino)methyl]N-(1H-tetrazol-5-yl)benzamide 798534-24-4P,
 N-[4-[(*trans*-4-tert-Butylcyclohexyl)[1-(5-trifluoromethoxy-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)benzamide 798534-25-5P,
 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(chloro-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)benzamide 798534-26-6P
 798534-27-7P, (2R)-3-[(4-[(5-Methyl-1H-benzimidazol-2-yl)(*trans*-4-
 tert-butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-28-8P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(methyl-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-29-9P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-dichloro-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-30-0P, N-[4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-dichloro-1H-benzimidazol-2-yl)amino)methyl]benzoyl]β-alanine
 798534-31-1P, (2R)-3-[(4-[(5,6-dichloro-1H-Benzimidazol-2-yl)(*trans*-4-tert-butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-32-4P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-dimethyl-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-33-5P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-dimethyl-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-34-6P, 798534-35-7P,
 (2R)-3-[(4-[(5,6-dimethyl-1H-Benzimidazol-2-yl)(*trans*-4-tert-
 butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-36-8P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-dimethyl-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-37-9P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-difluoro-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-38-0P, N-[4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-difluoro-1H-benzimidazol-2-yl)amino)methyl]benzoyl]β-alanine
 798534-39-1P, (2R)-3-[(4-[(5,6-difluoro-1H-Benzimidazol-2-yl)(*trans*-4-tert-butylcyclohexyl)amino)methyl]benzoyl]amino)-2-hydroxypropanoic acid
 798534-40-4P, 4-[(*trans*-4-tert-Butylcyclohexyl)[5-(6-difluoro-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-41-5P, N-[4-[(*trans*-4-tert-Butylcyclohexyl)[1-(6-dimethyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]β-alanine
 798534-42-6P, 4-[(*trans*-4-tert-Butylcyclohexyl)[1-(6-dimethyl-1H-benzimidazol-2-yl)amino)methyl]N-(1H-tetrazol-5-yl)methyl]benzamide

17 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 butylcyclohexyl)amino[methyl]benzyl]amino]-2-hydroxypropanoic acid
 798534-67-5, 4-[[trans-4-tert-Butylcyclohexyl](-6-hydroxy-1-
 methyl-1H-benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-
 yl]methyl]benzamide 798534-68-6,
 4-[[trans-4-tert-Butylcyclohexyl](5-[(n-propyl)oxy]-1-methyl-1H-
 benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-yl]benzamide
 798534-69-7, N-[4-[[trans-4-tert-Butylcyclohexyl](-5-[(n-
 propyl)oxy]-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- β -
 alanine 798534-70-0, (2R)-3-[[4-[[5-[(n-Propyl)oxy]-1-methyl-
 1H-Benzimidazol-2-yl](-trans-4-tert-
 butylcyclohexyl)amino]methyl]benzyl]amino]-2-hydroxypropanoic acid
 798534-71-1, 4-[[trans-4-tert-Butylcyclohexyl](5-[(n-propyl)oxy]-
 1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-[1H-tetrazol-5-
 yl]methyl]benzamide 798534-72-3.

4-[(trans-4-*tert*-Butylcyclohexyl)[5-(isopropoxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-[1H-tetrazol-5-yl]benzamide 798534-73-3P,
 N-[4-[(trans-4-*tert*-Butylcyclohexyl)[5-(isopropoxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- β -alanine
 798534-74-4P, (2R)-[3-[(4-[(5-(Isopropoxy)-1-methyl-1H-Benzimidazol-2-yl]trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
 798534-75-5P, 4-[(trans-4-*tert*-Butylcyclohexyl)[5-(isopropoxy)-1-methyl-1H-benzimidazol-2-yl]amino]N-[1H-tetrazol-5-yl]benzamide 798534-76-6P,
 N-[4-[(trans-4-*tert*-Butylcyclohexyl)[6-[(n-Propyl)oxy]-1-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- β -alanine
 798534-77-7P, (2R)-[3-[(4-[(6-[(n-Propyl)oxy]-1-methyl-1H-Benzimidazol-2-yl]trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
 798534-78-8P, 4-[(trans-4-*tert*-Butylcyclohexyl)[5-methoxy-1-methyl-1H-benzimidazol-2-yl]amino]N-[1H-tetrazol-5-yl]methyl]benzamide
 798534-79-9P, 4-[(trans-4-*tert*-Butylcyclohexyl)[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-[1H-tetrazol-5-yl]benzamide 798534-80-2P,
 N-[4-[(trans-4-*tert*-Butylcyclohexyl)[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- β -alanine
 798534-81-3P, (2R)-[3-[(4-[(5-Cyclopentyloxy)-1-methyl-1H-Benzimidazol-2-yl]trans-4-*tert*-butylcyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxypropanoic acid
 798534-82-4P, 4-[(trans-4-*tert*-Butylcyclohexyl)[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-[1H-tetrazol-5-yl]methyl]benzamide 798534-83-5P

4-[(trans-4-tert-Butylcyclohexyl)-5-(isobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino)methyl]-N-(1H-tetrazol-5-yl)benzamide 798534-84-6P,
 N-[4-[(trans-4-tert-Butylcyclohexyl)-5-(isobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino)methyl]benzoyl- β -alanine
 798534-85-7P, (2R)-3-[4-[(5-(Isobutoxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino)methyl]benzoyl]amino]-2-hydroxypropanoic acid 798534-86-8P,


4-[(trans-4-tert-Butylcyclohexyl)-5-(isobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino)methyl]-N-(1H-tetrazol-5-yl)methyl]benzamide
 798534-87-9P, 4-[(trans-4-tert-Butylcyclohexyl)-(6-benzyloxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798534-88-0P, 798534-89-1P,
 (2R)-3-[4-[(6-Benzyloxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 butylcyclohexyl)amino[methyl]benzoyl]amino]-2-hydroxypropanoic acid
 798534-90-4P, 4-[(trans-4-tert-Butylcyclohexyl){6-(isopropoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798534-91-5P 798534-92-6P,
 (2R)-3-[(4-[(6-(Isopropoxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)-2-hydroxypropanoic acid
 798534-93-7P, 4-[(trans-4-tert-Butylcyclohexyl){6-methoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798534-94-8P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-methoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798534-95-9P (2R)-3-[(4-[(6-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)-2-hydroxypropanoic acid
 798534-96-0P,
 (2R)-3-[(4-[(5-Benzoyloxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)-2-hydroxypropanoic acid
 798534-97-1P, 4-[(trans-4-tert-Butylcyclohexyl){6-(cyclopentenyl)oxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798534-98-2P,
 N-[4-[(trans-4-tert-Butylcyclohexyl){6-(cyclopentenyl)oxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798534-99-3P, (2R)-3-[(4-[(6-Cyclopentenyl)oxy-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)-2-hydroxypropanoic acid
 798534-100-4P, 4-[(trans-4-tert-Butylcyclohexyl){5-ethoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-01-0P, N-[4-[(trans-4-tert-Butylcyclohexyl){5-ethoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-02-1P, 4-[(trans-4-tert-Butylcyclohexyl){5-(cyclobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-03-2P, N-[4-[(trans-4-tert-Butylcyclohexyl){5-(cyclobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-04-3P, 4-[(trans-4-tert-Butylcyclohexyl){5-(cyclobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-05-4P 798535-06-5P,
 4-[(trans-4-tert-Butylcyclohexyl){5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-07-6P, N-[4-[(trans-4-tert-Butylcyclohexyl){5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-08-7P,
 (cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]benzoyl]-
 β-alanine 798535-09-8P,
 4-[(trans-4-tert-Butylcyclohexyl){5-[(2,2-difluoroethyl)oxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-09-8P 798535-10-1P,
 4-[(trans-4-tert-Butylcyclohexyl){5-(cyclobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-11-2P 798535-12-3P,
 4-[(trans-4-tert-Butylcyclohexyl){5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-13-4P, N-[4-[(trans-4-tert-Butylcyclohexyl){5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-14-5P,
 4-[(trans-4-tert-Butylcyclohexyl){6-ethoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (Continued)
 N-[4-[(trans-4-tert-Butylcyclohexyl){6-ethoxy-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798535-15-6P,
 N-[4-[(trans-4-tert-Butylcyclohexyl){6-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-17-8P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-18-9P,
 4-[(trans-4-tert-Butylcyclohexyl){6-(isobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798535-19-0P,
 N-[4-[(trans-4-tert-Butylcyclohexyl){6-(isobutoxy)-1-methyl-1H-benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-20-1P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy)-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-21-4P, 4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy)-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-22-5P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy)-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-23-6P, (2R)-3-[(4-[(6-Allyloxy-1-ethyl-1H-Benzimidazol-2-yl)(trans-4-tert-cyclohexyl)amino]methyl)benzoyl]amino)-2-hydroxypropanoic acid
 798535-24-7P, 4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy-1-ethyl-1H-Benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-25-8P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy-1-ethyl-1H-Benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-26-9P, N-[4-[(trans-4-tert-Butylcyclohexyl){6-(allyloxy-1-ethyl-1H-Benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-27-0P, (2R)-3-[(4-[(6-Difluoro-1-ethyl-1H-Benzimidazol-2-yl)(trans-4-tert-cyclohexyl)amino]methyl)benzoyl]amino)-2-hydroxypropanoic acid
 798535-28-1P, 4-[(trans-4-tert-Butylcyclohexyl){6-hydroxy-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-29-2P,
 N-[4-[(trans-4-tert-Butylcyclohexyl){6-hydroxy-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798535-30-5P,
 (2R)-3-[(4-[(6-Hydroxy-1-ethyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylcyclohexyl)amino]methyl)-2-hydroxypropanoic acid
 798535-31-6P, 4-[(trans-4-tert-Butylcyclohexyl){6-hydroxy-1-ethyl-1H-Benzimidazol-2-yl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-32-7P, N-[4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-33-8P, 4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-34-9P, N-[4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-35-0P, 4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-36-1P, N-[4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-37-2P, 4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 798535-38-3P, N-[4-[(4-[(4-Chlorophenoxy)-3-chlorophenyl](5-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-39-4P, 4-[(4-[(4-Cyclohexyl)phenyl](1H-benzimidazol-5-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798535-40-7P,
 N-[4-[(4-[(4-Cyclohexyl)phenyl](1H-benzimidazol-5-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-41-8P, (2R)-3-[(4-[(1H-benzimidazol-2-yl)amino-2-[(cyclohexyl)phenyl]methyl]benzoyl)amino]-2-hydroxypropanoic acid
 798535-42-9P, 4-[(4-[(4-Cyclohexyl)phenyl](1-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide 798535-43-0P,
 N-[4-[(4-Cyclohexyl)phenyl](1-methyl-1H-benzimidazol-2-yl)amino[methyl]}-N-(1H-tetrazol-5-yl)benzamide
 798535-44-1P, (2R)-3-[(4-[(1-Methyl-1H-Benzimidazol-2-yl)(4-(cyclohexyl)phenyl)amino]methyl)benzoyl]amino)-2-hydroxypropanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Theapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of benzimidazoles as glucagon receptor antagonists for treating type II diabetes mellitus and their compns. contg. them)
 RN 798535-46-7 CAPLUS
 CN Benzamide, 4-[(1H-benzimidazol-2-yl)[trans-4-(1,1-dimethyllethyl)cyclohexyl]amino[methyl]}-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798533-47-8 CAPLUS
 CN β-Alanine, N-[4-[(1H-benzimidazol-2-yl)[trans-4-(1,1-dimethyllethyl)cyclohexyl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798533-48-9 CAPLUS
 Benzamide, 4-[(1H-benzimidazol-2-yl)[trans-4-(1,1-dimethyllethyl)cyclohexyl]amino[methyl]}-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-49-0 CAPLUS
 Propionic acid, 3-[(4-[(1H-benzimidazol-2-yl)[trans-4-(1,1-dimethyllethyl)cyclohexyl]amino[methyl]}-N-(1H-tetrazol-5-yl)benzoyl]amino)-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-50-3 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-51-4 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-52-5 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, methyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-53-6 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-54-7 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-55-8 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-(2-hydroxyethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-56-9 CAPLUS
 CN Benzamide, 4-[[4-((1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-propen-1-yl)oxy]-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798533-57-0 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-58-1 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-59-2 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-60-5 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-61-6 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-62-7 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-63-8 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-64-9 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-yl)methyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-65-0 CAPLUS
 CN Propanoic acid,
 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-66-1 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-67-2 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-69-3 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-69-4 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl]benzylamino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-70-7 CAPLUS
 CN Benzamide, 4-[[1-cyclopentyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-71-8 CAPLUS
 CN β -Alanine, N-[4-[[1-cyclopentyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-72-9 CAPLUS
 CN Propanoic acid, 3-[[4-[[1-cyclopentyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzylamino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-73-0 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(phenylmethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-74-1 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(phenylmethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-75-2 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(phenylmethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-76-3 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(phenylmethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-77-4 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-78-5 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-79-6 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-80-9 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-81-0 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-82-1 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-83-2 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-84-3 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-85-4 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-86-5 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-87-6 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-88-7 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-hydroxyethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-89-8 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(2-hydroxyethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-90-1 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(3-hydroxypropyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-91-2 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(3-hydroxypropyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-92-3 CAPLUS
 CN Benzamide, 4-[[[2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-93-4 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-94-5 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[[4-(trifluoromethoxy)phenyl]methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-95-6 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-(4-(trifluoromethoxy)phenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798533-96-7 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-97-8 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-98-9 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-1H-benzimidazol-2-yl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798533-99-0 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-00-6 CAPLUS
 CN Benzamide, 4-[[[1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-01-7 CAPLUS
 CN β -Alanine, N-4-[[1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-02-8 CAPLUS
 CN Propanoic acid, 3-[[4-[[1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-03-9 CAPLUS
 CN Benzamide, 4-[[1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-04-0 CAPLUS
 CN β -Alanine, N-4-[[1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-05-1 CAPLUS
 CN Propanoic acid, 3-[[4-[[1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl](trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-06-2 CAPLUS
 CN Benzamide,
 4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-07-3 CAPLUS
 CN β -Alanine, N-[4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-09-4 CAPLUS
 CN Propanoic acid,
 3-[(4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl)benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-09-5 CAPLUS
 CN Benzamide,
 4-[(1-[(3,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-10-8 CAPLUS
 CN β -Alanine, N-[4-[(1-[(3,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-11-9 CAPLUS
 CN Propanoic acid,
 3-[(4-[(1-[(3,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl)benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-12-0 CAPLUS
 CN Benzamide, 4-[(1-[(4-cyanophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-13-1 CAPLUS
 CN β -Alanine, N-[4-[(1-[(4-cyanophenyl)methyl]-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-14-2 CAPLUS
 CN Propanoic acid, 3-[4-[[1-(4-cyanophenyl)methyl]-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-15-3 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-nitrophenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-16-4 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-nitrophenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-17-5 CAPLUS
 CN Propanoic acid, 3-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-nitrophenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-18-6 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-19-7 CAPLUS
 CN β -Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-20-0 CAPLUS
 CN Propanoic acid, 3-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 798534-21-1 CAPLUS
 CN β -Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][5-methyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 798534-22-2 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



RN 798534-23-3 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-(trifluoromethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-24-4 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-(trifluoromethoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798534-25-5 CAPLUS
 CN Benzamide, 4-[[((6-chloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798534-26-6 CAPLUS
 CN β -Alanine, N-[4-[(5-chloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798534-27-7 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 798534-28-8 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798534-29-9 CAPLUS
 CN Benzamide, 4-[[((5,6-dichloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-30-2 CAPLUS
 CN β -Alanine, N-[4-[(5,6-dichloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-31-3 CAPLUS
 CN Propanoic acid, 3-[(4-[(5,6-dichloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-32-4 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-33-5 CAPLUS
 CN Benzamide, 4-[(5,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-34-6 CAPLUS
 CN β -Alanine, N-4-[(5,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-35-7 CAPLUS
 CN Propanoic acid, 3-[(4-[(5,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-36-8 CAPLUS
 CN Benzamide, 4-[(5,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-37-9 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-38-0 CAPLUS
 CN β -Alanine, N-4-[(5,6-difluoro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-39-1 CAPLUS
 CN Propanoic acid, 3-[4-[(5,6-difluoro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-40-4 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-41-5 CAPLUS
 CN β -Alanine, N-[4-[(1,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-42-6 CAPLUS
 CN Benzamide, 4-[(1,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-43-7 CAPLUS
 CN Propanoic acid, 3-[4-[(1,6-dimethyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-44-8 CAPLUS
 CN β -Alanine, N-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-45-9 CAPLUS
 CN Benzamide, 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-46-0 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-47-1 CAPLUS
 CN β -Alanine, N-[4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-48-2 CAPLUS
 CN Propanoic acid,
 3-[(4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl)amino]-2-hydroxy-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-49-3 CAPLUS
 CN Benzamide,
 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-50-6 CAPLUS
 CN β -Alanine, N-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-51-7 CAPLUS
 CN Propanoic acid, 3-[(4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl)amino]-2-hydroxy-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-52-8 CAPLUS
 CN Benzamide,
 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1,5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-53-9 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-54-0 CAPLUS
 CN β -Alanine, N-[4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-55-1 CAPLUS
 CN Propanoic acid,
 3-[(4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-56-2 CAPLUS
 CN Propanoic acid,
 3-[(4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-57-3 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-58-4 CAPLUS
 CN Propanoic acid,
 3-[(4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-,
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-59-5 CAPLUS
 CN Benzamide, 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-60-8 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-61-9 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-62-0 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-71-1 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-72-2 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-73-3 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-74-4 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-75-5 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-76-6 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-propoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-77-7 CAPLUS
 CN Propanoic acid, 3-[[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-propoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-78-8 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-79-9 CAPLUS
 CN Benzamide, 4-[[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-80-2 CAPLUS
 CN β -Alanine, N-[4-[[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl] - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-81-3 CAPLUS
 CN Propanoic acid, 3-[4-[[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-82-4 CAPLUS
 CN Benzamide, 4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl) - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-83-5 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(2-methylpropoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-yl) - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-84-6 CAPLUS
 CN β -Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(2-methylpropoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl] - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-85-7 CAPLUS
 CN Propanoic acid, 3-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(2-methylpropoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-86-8 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(2-methylpropoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-yl) - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-87-9 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-yl) - (CA INDEX NAME)

Relative stereochemistry.




RN 798534-88-0 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-ylamino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-89-1 CAPLUS
 CN Propanoic acid,
 3-[(4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-ylamino]methyl]benzoyl)amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-90-4 CAPLUS
 CN Benzamide, 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(1-methylethoxy)-1H-benzimidazol-2-ylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-91-5 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(1-methylethoxy)-1H-benzimidazol-2-ylamino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-92-6 CAPLUS
 CN Propanoic acid,
 3-[(4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][1-methyl-6-(1-methylethoxy)-1H-benzimidazol-2-ylamino]methyl]benzoyl)amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-93-7 CAPLUS
 CN Benzamide,
 4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][6-methoxy-1-methyl-1H-benzimidazol-2-ylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798534-94-8 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][6-methoxy-1-methyl-1H-benzimidazol-2-ylamino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 798534-95-9 CAPLUS
 CN Propanoic acid,
 3-[(4-[[trans-4-(1,1-dimethylethyl)cyclohexyl][6-methoxy-1-methyl-1H-benzimidazol-2-ylamino]methyl]benzoyl)amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798534-96-0 CAPLUS
CN Propanoic acid,

3-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-

(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 798534-97-1 CAPLUS
CN Benzamide,

4-[(6-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798534-98-2 CAPLUS

β -Alanine, N-[4-[(6-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 798534-99-3 CAPLUS


Propanoic acid, 3-[4-[(6-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798535-00-9 CAPLUS
CN Benzamide, 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(5-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.



RN 798535-01-0 CAPLUS
CN β -Alanine, N-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(5-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-02-1 CAPLUS

Benzamide, 4-[(5-(cyclobutyloxy)-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-03-2 CAPLUS

β -Alanine, N-[4-[(5-(cyclobutyloxy)-1-methyl-1H-benzimidazol-2-yl)[trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

(Continued)



RN 798535-04-3 CAPLUS
 CN Benzamide, 4-[[5-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-05-4 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-06-5 CAPLUS
 CN Benzamide, 4-[[5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-07-6 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-08-7 CAPLUS
 CN Benzamide, 4-[[5-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-09-8 CAPLUS
 CN β -Alanine, N-[4-[[5-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-10-1 CAPLUS
 CN Benzamide, 4-[[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-11-2 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-12-3 CAPLUS
 CN Benzamide, 4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-13-4 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-14-5 CAPLUS
 CN Benzamide, 4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-15-6 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](6-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-16-7 CAPLUS
 CN Benzamide, 4-[[6-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-17-8 CAPLUS
 CN β -Alanine, N-[4-[[6-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][trans-4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798535-18-9 CAPLUS
 CN Benzamide, 4-[[5-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-19-0 CAPLUS
 CN β -Alanine, N-[4-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-(2-methylpropoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-20-3 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1-ethyl-1H-benzimidazol-2-yl){trans-4-(1,1-dimethylethyl)cyclohexyl]amino}methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-21-4 CAPLUS
 CN Benzamide,
 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-22-5 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-23-6 CAPLUS
 CN Propionic acid,
 3-[(4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798535-24-7 CAPLUS
 CN Benzamide,
 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-25-8 CAPLUS
 CN Benzamide, 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-26-9 CAPLUS
 CN β -Alanine, N-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-27-0 CAPLUS
 CN Propionic acid, 3-[(4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798535-28-1 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-29-2 CAPLUS
 CN β -Alanine, N-[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino)methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 798535-30-5 CAPLUS
 CN Propanoic acid, 3-[[4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino)methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798535-31-6 CAPLUS
 CN Benzamide, 4-[[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino)methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)


Relative stereochemistry.




RN 798535-32-7 CAPLUS
 CN β -Alanine, N-[4-[[[3-chloro-4-(4-chlorophenoxy)phenyl](5-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 798535-33-8 CAPLUS
 CN Benzamide, 4-[[[3-chloro-4-(4-chlorophenoxy)phenyl](6-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-34-9 CAPLUS
 CN β -Alanine, N-[4-[[[3-chloro-4-(4-chlorophenoxy)phenyl][5-(trifluoromethoxy)-1H-benzimidazol-2-yl]amino)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 798535-35-0 CAPLUS
 CN Benzamide, 4-[[[6-chloro-1H-benzimidazol-2-yl][3-chloro-4-(4-chlorophenoxy)phenyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-36-1 CAPLUS
 CN β -Alanine, N-[4-[(5-chloro-1H-benzimidazol-2-yl) [3-chloro-4-(4-chlorophenoxy)phenyl]amino]methyl]benzoyl- (9CI) (CA INDEX NAME)




RN 798535-37-2 CAPLUS
 CN Benzamide, 4-[[13-chloro-4-(4-chlorophenoxy)phenyl](1,5-dimethyl-1H-benzimidazol-2-yl)amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-38-3 CAPLUS
 CN β -Alanine, N-[4-[[3-chloro-4-(4-chlorophenoxy)phenyl](1,5-dimethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)



RN 798535-39-4 CAPLUS
 CN Benzamide,
 4-[[1H-benzimidazol-2-yl(4-cyclohexylphenyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-40-7 CAPLUS
 CN β -Alanine, N-[4-[[1H-benzimidazol-2-yl(4-cyclohexylphenyl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798535-41-8 CAPLUS
 CN Propanoic acid, 3-[[4-[[1H-benzimidazol-2-yl(4-cyclohexylphenyl)amino]methyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 798535-42-9 CAPLUS
 CN Benzamide, 4-[[4-cyclohexylphenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-43-0 CAPLUS
 CN β -Alanine, N-[4-[[4-cyclohexylphenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)



RN 798535-44-1 CAPLUS

CN Propanoic acid, 3-[(4-[(4-cyclohexylphenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 798535-45-2P, 4-[(4-Cyclohexylphenyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-46-3P, N-[(4-[(4-Cyclohexylphenyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]- β -alanine
 798535-47-4P, 4-[(4-[(4-Cyclohexylphenyl)(5-[(n-propyl)oxy]-1-methyl-1H-benzimidazol-2-yl)amino]methyl)-N-(1H-tetrazol-5-yl)benzamide
 798535-48-5P, 4-[(4-[(4-[(Trifluoromethoxy)phenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-49-6P, (2R)-3-[(4-[(1-Methyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-50-9P, 4-[(4-[(Trifluoromethoxy)phenyl](6-allyloxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl)-N-(1H-tetrazol-5-yl)benzamide

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 798535-77-0P, 4-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine
 798535-78-1P, N-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine
 798535-79-2P, 4-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine

4-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine
 798535-80-5P, N-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine
 798535-81-6P, 4-[(6-Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methylbenzoyl- β -alanine

4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(diphenylmethyl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-82-7P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-(cyclohexylphenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-83-8P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(3-chlorobenzyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-84-9P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-(trifluoromethoxy)cyclohexyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-85-0P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-bromophenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-86-1P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-(tert-butylphenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-87-2P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(3,5-dichlorophenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-88-3P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-chlorobenzyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-89-4P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(2-chlorobenzyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-90-7P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-phenyl)cyclohexyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-91-8P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(6-fluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-92-9P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-phenyl)phenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-93-0P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-isopropylphenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-94-1P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(2-phenyl)ethyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-95-2P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(3-phenylpropyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-96-3P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-phenylbutyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-97-4P, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(2-4-chlorophenyl)ethyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-98-5P, 4-[(5-[(n-Propyl)oxy]-1-methyl-1H-Benzimidazol-2-yl)(3,5-dichlorophenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798535-99-6P, 4-[(5-(Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(3,5-dichlorophenyl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798536-00-2P, 4-[(5-(Methyl-1H-Benzimidazol-2-yl)(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798536-01-3P, 4-[(5-(Methyl-1H-Benzimidazol-2-yl)(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798536-02-4P, 4-[(5-(Methyl-1H-Benzimidazol-2-yl)(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide
 798536-03-5P, 4-[(5-(Methyl-1H-Benzimidazol-2-yl)(6-bromo-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl]-N-(1H-tetrazol-5-yl)benzamide

798535-51-0P, 798535-52-1P, (2R)-3-[(4-[(6-Allyloxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-53-2P, 4-[(4-(Trifluoromethoxy)phenyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-54-3P, 4-[(4-(Trifluoromethoxy)phenyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-55-4P, 4-[(4-(Trifluoromethoxy)phenyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-56-5P, 4-[(4-(Trifluoromethoxy)phenyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-57-6P, N-[(4-(Trifluoromethoxy)phenyl)(6-benzoyloxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 798535-58-7P, N-[(4-(Trifluoromethoxy)phenyl)(6-benzoyloxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine

4-[(2-Indanyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-59-8P, 4-[(2-Indanyl)(6-allyloxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-60-1P, N-[(2-Indanyl)(6-allyloxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 798535-61-2P, (2R)-3-[(4-[(6-Allyloxy-1-methyl-1H-Benzimidazol-2-yl)(2-indanyl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-62-3P, 4-[(3,5-Dichlorophenyl)(1H-benzimidazol-2-yl)amino]methyl- β -alanine
 798535-63-4P, N-[(3,5-Dichlorophenyl)(1H-benzimidazol-2-yl)amino]methyl- β -alanine
 798535-64-5P, (2R)-3-[(4-[(1-Methyl-1H-Benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-65-6P, 4-[(3,5-Dichlorophenyl)(1H-benzimidazol-2-yl)amino]methyl- β -alanine
 798535-66-7P, 798535-67-8P, N-[(4-Cyclohex-1-en-1-ylphenyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 798535-68-9P, N-[(4-Cyclohex-1-en-1-ylphenyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 4-[(3,5-Dichlorophenyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-69-0P, 4-[(3,5-Dichlorophenyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 3-Bromo-4-[(4-tert-butylycyclohexyl)(5-methoxy-1-methyl-1H-Benzimidazol-2-yl)amino]methyl-N-(1H-tetrazol-5-yl)benzamide
 798535-70-3P, 3-Bromo-4-[(4-tert-butylycyclohexyl)(5-cyclopentyl)oxy-1-methyl-1H-Benzimidazol-2-yl]amino-2-hydroxypropanoic acid
 798535-71-4P, N-[(4-[(1-Ethyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methyl)benzoyl]glycine
 798535-72-5P, 798535-73-6P, 4-[(5-Bromo-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methyl- β -alanine
 798535-74-7P, N-[(4-[(5-Bromo-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methyl)benzoyl]amino-2-hydroxypropanoic acid
 798535-75-8P, 4-[(trans-4-tert-Butylcyclohexyl)(1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 798535-76-9P, N-[(6-[(2,2-Difluoroethyl)oxy]-1-methyl-1H-Benzimidazol-2-yl)amino]methyl- β -alanine
 N-[(6-[(2,2-Difluoroethyl)oxy]-1-methyl-1H-Benzimidazol-2-yl)(trans-4-tert-butylycyclohexyl)amino]methyl- β -alanine

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 798536-04-6B, 4-[(5-Methoxy-1-methyl-1H-Benzimidazol-2-yl)(4-trifluoromethoxyphenyl)amino]methyl- β -alanine
 798536-05-7P, 4-[(5-(n-Propyl)oxy)-1-methyl-1H-Benzimidazol-2-yl)(4-(trifluoromethoxyphenyl)amino]methyl- β -alanine
 798536-06-8P, 4-[(5-(Cyclohexyloxy)-1-methyl-1H-Benzimidazol-2-yl)(4-(trifluoromethoxyphenyl)amino)methyl- β -alanine
 798536-07-9P, 798536-08-0P, 798536-09-1P, 798536-10-4P, 798536-11-5P, 798536-12-6P
 798536-13-7P, 798536-14-8P, 798536-15-9P, 798536-16-10P, 798536-17-11P, 798536-18-12P
 798536-21-17P, 798536-22-18P, 798536-23-19P, 798536-24-20P, 798536-31-39P, 798536-32-40P
 798536-33-17P, 798536-34-28P, 798536-35-33P, 798536-36-4P, 798536-37-35P, 798536-38-6P
 798536-39-7P, 798536-40-8P, 798536-41-1P, 798536-42-2P, 798536-43-3P, 798536-44-4P
 798536-45-5P, 798536-46-6P, 798536-47-7P, 798536-48-8P, 798536-49-9P, 798536-50-2P
 798536-51-3P, 798536-52-4P, 798536-53-5P, 798536-54-6P, 798536-55-7P, 798536-56-8P
 798536-57-9P, 798536-58-0P, 798536-59-1P, 798536-60-4P, 798536-61-5P, 798536-62-6P
 798536-63-7P, 798536-64-8P, 798536-65-9P, 798536-66-0P, 798536-67-1P, 798536-68-2P
 798536-69-3P, 798536-70-6P, 798536-71-7P, 798536-72-8P, 798536-73-9P, 798536-74-0P
 798536-75-1P, 798536-76-2P, 798536-77-3P, 798536-78-4P, 798536-79-5P, 798536-80-6P
 798536-81-9P, 798536-82-0P, 798536-83-1P, 798536-84-2P, 798536-85-3P, 798536-86-4P
 798536-87-5P, 798536-88-6P, 798536-89-7P, 798536-90-0P, 798536-91-1P, 798536-92-2P
 798536-93-3P, 798536-94-4P, 798536-95-5P, 798536-96-6P, 798536-97-7P, 798536-98-8P
 798536-99-9P, 798536-100-0P, 798537-01-1P, 798537-02-2P, 798537-03-3P, 798537-04-9P
 798537-05-0P, 798537-06-1P, 798537-07-2P, 798537-08-3P, 798537-09-4P, 798537-10-7P
 798537-11-8P, 798537-12-9P, 798537-13-0P, 798537-14-1P, 798537-15-2P, 798537-16-3P
 798537-17-4P, 798537-18-5P, 798537-19-6P, 798537-20-9P, 798537-21-0P, 798537-22-1P
 798537-23-2P, 798537-24-3P, 798537-25-4P, 798537-26-5P, 798537-27-6P, 798537-28-7P
 798537-29-8P, 798537-30-1P, 798537-31-2P, 798537-32-3P, 798537-33-4P, 798537-34-5P
 798537-35-6P, 798537-36-7P, 798537-37-8P, 798537-38-9P, 798537-39-0P, 798537-40-3P
 798537-41-4P, 798537-42-5P, 798537-43-6P, 798537-44-7P, 798537-45-8P, 798537-46-9P
 798537-47-0P, 798537-48-1P, 798537-49-2P, 798537-50-5P, 798537-51-6P, 798537-52-7P
 798537-53-8P, 798537-54-9P, 798537-55-0P, 798537-56-1P, 798537-57-2P, 798537-58-3P
 798537-59-4P, 798537-60-5P, 798537-61-6P, 798537-62-7P, 798537-63-8P, 798537-64-1P
 798537-65-2P, 798537-66-3P, 798537-67-4P


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

798537-68-5P 798537-69-6P 798537-70-9P
 798537-71-0P 798537-72-1P 798537-73-2P
 798537-74-3P 798537-75-4P 798537-76-5P
 798537-77-6P 798537-78-7P 798537-79-8P
 798537-80-1P 798537-81-2P 798537-82-3P
 798537-83-4P 798537-84-5P 798537-85-6P
 798537-86-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of benzimidazoles as glucagon receptor antagonists for treating type II diabetes mellitus and their compns. contg. them)

RN 798535-45-2 CAPLUS


CN Benzamide, 4-[(4-cyclohexylphenyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl- (CA INDEX NAME)



RN 798535-46-3 CAPLUS


CN β -Alanine, N-[4-[(4-cyclohexylphenyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-47-4 CAPLUS


CN Benzamide, 4-[(4-cyclohexylphenyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl- (CA INDEX NAME)



RN 798535-48-5 CAPLUS

CN Benzamide, 4-[(1-methyl-1H-benzimidazol-2-yl)(4-(trifluoromethoxy)phenyl)amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-49-6 CAPLUS


CN Propanoic acid, 2-hydroxy-3-[(4-[(1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl)benzoyl]amino-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 798535-50-9 CAPLUS


CN Benzamide, 4-[(1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798535-51-0 CAPLUS

CN β -Alanine, N-[4-[(1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-52-1 CAPLUS


CN Propanoic acid, 2-hydroxy-3-[(4-[(1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl)benzoyl]amino-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798535-53-2 CAPLUS


CN Benzamide, 4-[(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798535-54-3 CAPLUS
 CN Benzamide, 4-[(1-methyl-6-propoxy-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-55-4 CAPLUS
 CN β -Alanine, N-[4-[(1-methyl-6-propoxy-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]benzoyl- (CA INDEX NAME)



RN 798535-56-5 CAPLUS
 CN Benzamide, 4-[(1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 798535-57-6 CAPLUS
 CN β -Alanine, N-[4-[(1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]benzoyl- (CA INDEX NAME)



RN 798535-58-7 CAPLUS
 CN Benzamide, 4-[(2,3-dihydro-1H-inden-2-yl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798535-59-8 CAPLUS
 CN Benzamide, 4-[(2,3-dihydro-1H-inden-2-yl)[1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-60-1 CAPLUS
 CN β -Alanine, N-[4-[(2,3-dihydro-1H-inden-2-yl)[1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798535-61-2 CAPLUS
 CN Propionic acid, 3-[(4-[(2,3-dihydro-1H-inden-2-yl)[1-methyl-6-(2-propen-1-yloxy)-1H-benzimidazol-2-yl]amino]methyl)benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 798535-62-3 CAPLUS
 CN Benzamide, 4-[(1H-benzimidazol-2-yl(3,5-dichlorophenyl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-63-4 CAPLUS
 CN β-Alanine, N-[4-[(3,5-dichlorophenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798535-64-5 CAPLUS
 CN Propanoic acid, 3-[(4-[(3,5-dichlorophenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 798535-65-6 CAPLUS
 CN Benzamide, 4-[(1H-benzimidazol-2-yl)(3,5-dichlorophenyl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798535-66-7 CAPLUS
 CN Benzamide, 4-[(4-[(1-cyclohexen-1-yl)phenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl)-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-67-0 CAPLUS
 CN β-Alanine, N-[4-[(4-(1-cyclohexen-1-yl)phenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798535-68-9 CAPLUS
 CN Benzamide, 4-[(3,5-dichlorophenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798535-69-0 CAPLUS
 CN Benzamide, 3-bromo-4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-




RN 798535-70-3 CAPLUS
 CN Benzamide, 3-bromo-4-[(5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-71-4 CAPLUS
 CN Glycine, N-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

Relative stereochemistry.




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798535-72-5 CAPLUS
 CN Butanoic acid,
 4-[[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)

Relative stereochemistry.



RN 798535-73-6 CAPLUS
 CN Benzamide, 4-[[5-bromo-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-74-7 CAPLUS
 CN β -Alanine, N-[4-[[5-bromo-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-75-8 CAPLUS
 CN Benzamide, 4-[[6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-76-9 CAPLUS
 CN β -Alanine, N-[4-[[6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-77-0 CAPLUS
 CN Benzamide, 4-[[6-(cyclohexyloxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.



RN 798535-78-1 CAPLUS
 CN β -Alanine, N-[4-[[6-(cyclohexyloxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]- (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-79-2 CAPLUS
 CN Benzamide,
 4-[[6-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


Relative stereochemistry.




RN 798535-80-5 CAPLUS
 CN β -Alanine, N-[4-[[6-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl)(trans-4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-81-6 CAPLUS
CN Benzamide, 4-[(diphenylmethyl) (5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl (CA INDEX NAME)




RN 798535-82-7 CAPLUS
CN Benzamide, 4-[(4-cyclohexylphenyl) [5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl - (CA INDEX NAME




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798535-83-8 CAPLUS
CN Benzamide,
4-[[[(3-chlorophenyl)methyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-84-9 CAPLUS
CN Benzamide, 4-[[1H-benzimidazol-2-yl[4-
-(trifluoromethyl) cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX
NAME)




RN 798535-85-0 CAPLUS
CN Benzamide,
4-[(4-(bromophenyl)(1-methyl-1H-benzimidazol-2-yl)amino)methyl]-
N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CACPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-86-1 CAPLUS
CN Benzamide, 4-[[4-(1,1-dimethylethyl)phenyl](1-methyl-1H-benzimidazol-2-yl)aminomethyl]N-2H-tetrazol-5-yl (CA INDEX NAME)






RN 798535-87-2 CAPLUS
CN Benzamide, 4-[(5,5-dichlorophenyl) (5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-88-3 CAPLUS
CN Benzamide,
4-[[[(4-chlorophenyl)methyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)methyl]methyl]N,N'-bis(4-chlorophenyl)-N,N'-diphenylbenzidine (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPIUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798535-91-8 CAPLUS
 CN Benzamide, 4-[(6-fluoro-1,2,3,4-tetrahydro-2-naphthalenyl) (1-methyl-1H-benzimidazol-2-yl)amino]ethyl 3-(4-methoxyphenyl)propanoate (CN, INN, NAME)




RN 798535-92-9 CAPLUS
 CN Benzamide, 4-[[[1,1'-biphenyl]-4-yl(1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-93-0 CAPLUS
 CN Benzamide, 4-[[[1-methyl-1H-benzimidazol-2-yl][4-(1-methyl ethyl)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798535-97-4 CAPLUS
 CN Benzamide, 4-[[[2-(4-chlorophenyl)ethyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-98-5 CAPLUS
 CN Benzamide, 4-[[[3,5-dichlorophenyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-99-6 CAPLUS
 CN Benzamide, 4-[[[5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl](3,5-dichlorophenyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-94-1 CAPLUS
 CN Benzamide, 4-[[[1-methyl-1H-benzimidazol-2-yl](2-phenylethyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-95-2 CAPLUS
 CN Benzamide, 4-[[[1-methyl-1H-benzimidazol-2-yl](3-phenylpropyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798535-96-3 CAPLUS
 CN Benzamide, 4-[[[1-methyl-1H-benzimidazol-2-yl](4-phenylbutyl)amino]methyl]-



RN 798536-00-2 CAPLUS
 CN Benzamide, 4-[[[6-bromo-1,2,3,4-tetrahydro-2-naphthalenyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-01-3 CAPLUS
 CN Benzamide, 4-[[[1-methyl-5-(trifluoromethoxy)-1H-benzimidazol-2-yl][4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-02-4 CAPLUS
 CN Benzamide, 4-[(1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798536-03-5 CAPLUS
 CN Benzamide, 4-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-04-6 CAPLUS
 CN Benzamide, 4-[(5-methoxy-1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 798536-05-7 CAPLUS
 CN Benzamide, 4-[(1-methyl-5-propoxy-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-06-8 CAPLUS
 CN Benzamide, 4-[(5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798536-07-9 CAPLUS
 CN β -Alanine, N-[4-[(4-cyclohexylphenyl)(5-(cyclopentyloxy)-1-methyl-1H-


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

RN 798536-08-0 CAPLUS
 CN β -Alanine, N-[4-[(4-cyclohexylphenyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-09-1 CAPLUS
 CN β -Alanine, N-[4-[(1-methyl-1H-benzimidazol-2-yl)tricyclo[3.3.1.1,7]dec-2-ylamino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





RN 798536-10-4 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)phenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)





RN 798536-11-5 CAPLUS
 CN β -Alanine, N-[4-[(1-methyl-1H-benzimidazol-2-yl)(4-phenylcyclohexyl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-12-6 CAPLUS
 CN β -Alanine, N-[4-[(6-fluoro-1,2,3,4-tetrahydro-2-naphthalenyl)(1-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)RN 798536-13-7 CAPLUS
CN β -Alanine, N-[4-[[[1,1'-biphenyl]-4-yl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)RN 798536-14-8 CAPLUS
CN β -Alanine, N-[4-[(1-methyl-1H-benzimidazol-2-yl){4-(1-methylethyl)phenyl}amino]methyl]benzoyl]- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-15-9 CAPLUS
CN β -Alanine, N-[4-[[2-(4-chlorophenyl)ethyl](1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)RN 798536-16-0 CAPLUS
CN β -Alanine, N-[4-[(5-methoxy-1-methyl-1H-benzimidazol-2-yl){4-(trifluoromethoxy)phenyl}amino]methyl]benzoyl]- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-17-1 CAPLUS
CN Benzamide, 4-[1-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-N-2H-tetrazol-5-yl-, (-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

RN 798536-18-2 CAPLUS
CN Benzamide, 4-[1-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-N-2H-tetrazol-5-yl-, (+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-21-7 CAPLUS
CN β -Alanine, N-[4-[[1-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]benzoyl]- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.

RN 798536-22-8 CAPLUS
CN β -Alanine, N-[4-[[1-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]benzoyl]- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


RN 798536-23-9 CAPLUS
CN Propionic acid, 3-[[4-[(1R)-1-[(trans-4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 798536-24-0 CAPLUS
 CN Propanoic acid, 3-[4-[(1S)-1-[[trans-4-(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino]ethyl]benzoyl]amino]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 798536-31-9 CAPLUS
 CN β -Alanine, N-[4-[(1,1-dimethylethyl)cyclohexyl](5-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (9CI) (CA INDEX NAME)



RN 798536-32-0 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](6-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-33-1 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](6-(trifluoromethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-34-2 CAPLUS
 CN β -Alanine, N-[4-[(1,1-dimethylethyl)cyclohexyl](5-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


(trifluoromethoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (9CI) (CA INDEX NAME)



RN 798536-35-3 CAPLUS
 CN Benzamide, 4-[[4-(1,6-dimethyl-1H-benzimidazol-2-yl)[4-(1,1-dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-36-4 CAPLUS
 CN Benzamide, 4-[[4-(6-chloro-1H-benzimidazol-2-yl)[4-(1,1-dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-37-5 CAPLUS
 CN β -Alanine, N-[4-[(1,6-dimethyl-1H-benzimidazol-2-yl)[4-(1,1-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-38-6 CAPLUS
 CN β -Alanine, N-[4-[(5-chloro-1H-benzimidazol-2-yl)[4-(1,1-dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]benzoyl- (9CI) (CA INDEX NAME)




RN 798536-39-7 CAPLUS
 CN Benzamide, 4-[[1H-benzimidazol-2-yl][4-(1,1-dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-40-0 CAPLUS
 CN β -Alanine, N-[4-[[1H-benzimidazol-2-yl][4-(1,1-dimethyl-1H-benzimidazol-2-yl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-41-1 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-42-2 CAPLUS
 CN Acetic acid, [(4-[(1,1-dimethylethyl)cyclohexyl](1-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]amino]hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 798536-43-3 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-44-4 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)



CN Acetic acid, [(4-[(1,6-dimethyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-46-6 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-47-7 CAPLUS
 CN Benzamide,
 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)



RN 798536-49-9 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-50-2 CAPLUS
 CN Benzamide,
 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-51-3 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-propyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-52-4 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-propyl-1H-benzimidazol-2-yl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-53-5 CAPLUS
 CN Acetic acid, [(4-[(1,1-dimethylethyl)cyclohexyl](5-methyl-1-propyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798536-57-9 CAPLUS
 CN Acetic acid, [(4-[(1-cyclopentyl-5-methyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-58-0 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-ethyl-5-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-59-1 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-(phenylmethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798536-54-6 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](5-methyl-1-propyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-55-7 CAPLUS
 CN Benzamide, 4-[(1-cyclopentyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-56-8 CAPLUS
 CN β -Alanine, N-[4-[(1-cyclopentyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]-


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798536-60-4 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-(phenylmethyl)-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-61-5 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-(phenylmethyl)-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-62-6 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-(phenylmethyl)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-63-7 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl-N-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 798536-64-8 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-65-9 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-69-2 CAPLUS
 CN Acetic acid, [(4-[(1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl)benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-69-3 CAPLUS
 CN Benzamide,
 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-70-6 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl-N-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 798536-66-0 CAPLUS
 CN Acetic acid,
 [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-methylpropyl)-1H-benzimidazol-2-yl]amino]methyl)benzoyl]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-67-1 CAPLUS
 CN Benzamide, 4-[(4-(1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-71-7 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-72-8 CAPLUS
 CN Acetic acid,
 [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl)benzoyl]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-73-9 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-fluoroethyl)-1H-benzimidazol-2-yl]amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-74-0 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-75-1 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-76-2 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-propenyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-77-3 CAPLUS
 CN Acetic acid, [(4-[(1H-benzimidazol-2-yl)(4-cyclohexylphenyl)amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-78-4 CAPLUS
 CN Acetic acid, [(4-[(4-cyclohexylphenyl)(1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-79-5 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-80-8 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-81-9 CAPLUS
 CN β -Alanine, N-[4-[(5,6-dichloro-1H-benzimidazol-2-yl)[4-(1,1-



RN 798536-82-0 CAPLUS
 CN Acetic acid, [(4-[(5,6-dichloro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-83-1 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1-ethyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-84-2 CAPLUS
 CN Benzamide, 4-[(5,6-dimethyl-1H-benzimidazol-2-yl)[4-(1,1-


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798536-85-3 CAPLUS
 CN Benzamide, 4-[(5,6-dimethyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)



RN 798536-85-3 CAPLUS
 CN Benzamide, 4-[(5,6-dimethyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-86-4 CAPLUS
 CN β -Alanine, N-[4-[(5,6-dimethyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl]benzoyl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-90-0 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-hydroxyethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-91-1 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(2-hydroxyethyl)-1H-benzimidazol-2-yl]amino]methyl)benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-92-2 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-(5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798536-87-5 CAPLUS
 CN Acetic acid, [(4-[(5,6-dimethyl-1H-benzimidazol-2-yl)(4-(1,1-dimethylethyl)cyclohexyl)amino]methyl)benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-88-6 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethyl-1H-benzimidazol-2-yl)amino)ethyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-89-7 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethyl-1H-benzimidazol-2-yl)amino)ethyl][1-(2-hydroxyethyl)-1H-benzimidazol-2-yl]amino]N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798536-93-3 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethyl-1H-benzimidazol-2-yl)amino)ethyl][1-(5,6-trimethyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798536-94-4 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethyl-1H-benzimidazol-2-yl)amino)ethyl]benzoyl]- (CA INDEX NAME)




RN 798536-95-5 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethyl-1H-benzimidazol-2-yl)amino)ethyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



RN 798536-96-6 CAPLUS
 CN Benzamide, 4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798536-97-7 CAPLUS
 CN β -Alanine, N-[4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798536-98-8 CAPLUS

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Acetic acid, [(4-[(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl)benzoyl]hydroxy- (9CI) (CA INDEX NAME)




RN 798536-99-9 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-00-5 CAPLUS
 CN β -Alanine, N-[4-[(5,6-difluoro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-01-6 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798537-02-7 CAPLUS
 CN Acetic acid, [(4-[(5,6-difluoro-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl)benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-03-8 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-04-9 CAPLUS
 CN Propionic acid, 3-[(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-1H-benzimidazol-2-yl)amino]ethyl)benzoyl]amino]-2-hydroxy- (CA INDEX NAME)




RN 798537-05-0 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-06-1 CAPLUS
 CN β -Alanine, N-[4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-07-2 CAPLUS
 CN Acetic acid, [(4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl) [4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-08-3 CAPLUS
 CN Benzamide, 4-[(5,6-difluoro-1-(3-hydroxypropyl)-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-12-9 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-[(4-(trifluoromethoxy)phenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-13-0 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-[(4-(trifluoromethoxy)phenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-14-1 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-[(4-(trifluoromethoxy)phenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798537-09-4 CAPLUS
 CN Acetic acid, [(4-[(5,6-difluoro-1-(3-hydroxypropyl)-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexylamino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-10-7 CAPLUS
 CN Acetic acid, hydroxy[(4-[(1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethoxy)phenyl]amino]methyl]benzoyl)amino]- (9CI) (CA INDEX NAME)




RN 798537-11-8 CAPLUS
 CN Benzamide, 4-[(1-[(2-(dimethylamino)ethyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexylamino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-15-2 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-phenyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-16-3 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[5-methyl-1-phenyl-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-yl)methyl- (CA INDEX NAME)




RN 798537-17-4 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-phenyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-18-5 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-phenyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-19-6 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propenyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798537-20-9 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propenyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)




RN 798537-21-0 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-(2-propenyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-22-1 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5-methyl-6-(2-propenyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-23-2 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-24-3 CAPLUS
 CN Benzamide,
 4-[(5,6-difluoro-1-methyl-1H-benzimidazol-2-yl)(2,3-dihydro-1H-inden-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-25-4 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-26-5 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN


(Continued)



RN 798537-27-6 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-28-7 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-5,6-difluoro-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-29-8 CAPLUS
 CN Acetic acid,
 [[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-6-hydroxy-1H-


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)



RN 798537-30-1 CAPLUS
 Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-6-hydroxy-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798537-31-2 CAPLUS
 Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798537-32-3 CAPLUS
 CN Acetic acid,
 [[4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-33-4 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-34-5 CAPLUS
 CN β -Alanine, N-[4-[(1H-benzimidazol-2-yl)(3,5-dichlorophenyl)amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-35-6 CAPLUS
 CN Acetic acid, [[4-[(1H-benzimidazol-2-yl)(3,5-dichlorophenyl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-36-7 CAPLUS
 Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-37-8 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-38-9 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798537-39-0 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-40-3 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-41-4 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-42-5 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-43-6 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-44-7 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798537-45-8 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-propenyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-46-9 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1,5-dimethyl-6-(2-propen-1-yl)-1H-benzimidazol-2-yl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798537-47-0 CAPLUS
 CN Benzamide, 4-[(1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-49-1 CAPLUS
 CN Benzamide, 4-[(1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-49-2 CAPLUS
 CN Benzamide, 4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-50-5 CAPLUS
 CN Acetic acid, [(4-[(1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-51-6 CAPLUS
 CN Acetic acid, [(4-[(1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-52-7 CAPLUS
 CN Acetic acid, [(4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-53-8 CAPLUS
 CN β -Alanine, N-[4-[(1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]- (CA INDEX NAME)




RN 798537-54-9 CAPLUS
 CN β -Alanine, N-[4-[(1-[(3-chlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]- (CA INDEX NAME)



RN 798537-55-0 CAPLUS
 CN β -Alanine, N-[4-[(1-[(2,4-dichlorophenyl)methyl]-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino)methyl]benzoyl]- (CA INDEX NAME)




RN 798537-56-1 CAPLUS
 CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-57-2 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-58-3 CAPLUS
 CN Acetic acid, 4-[[4-(1,1-dimethylethyl)cyclohexyl](6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-59-4 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](6-hydroxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798537-60-7 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-61-8 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)




RN 798537-62-9 CAPLUS
 CN β -Alanine, N-4-[[4-(1,1-dimethylethyl)cyclohexyl](1-phenyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-63-0 CAPLUS
 CN Acetic acid, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-propoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-64-1 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-65-2 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)





RN 798537-66-3 CAPLUS
 CN β -Alanine, N-4-[[4-(1,1-dimethylethyl)cyclohexyl][5-(1-methylethoxy)-1-phenyl-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)






RN 798537-67-4 CAPLUS
 CN Acetic acid, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-5-(1-methylethoxy)-1H-benzimidazol-2-yl)amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)







RN 798537-68-5 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl](1-methyl-6-propoxy-1H-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)RN 798537-69-6 CAPLUS
CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-phenyl-6-proxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)RN 798537-70-9 CAPLUS
CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-methyl-6-proxy-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 798537-71-0 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)RN 798537-72-1 CAPLUS
CN Benzamide, 4-[(5-(cyclopentyl)oxy-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)

RN 798537-73-2 CAPLUS


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzamide, 4-[(5-(cyclopentyl)oxy-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-(2H-tetrazol-5-ylmethyl)- (CA INDEX NAME)RN 798537-74-3 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(2-methyloxyproxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)RN 798537-77-6 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(1-methylethoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)RN 798537-78-7 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[6-methoxy-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)RN 798537-79-8 CAPLUS
CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)

RN 798537-76-5 CAPLUS

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798537-80-1 CAPLUS
 CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(1-methoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)




RN 798537-81-2 CAPLUS
 CN β -Alanine, N-[4-[(1,1-dimethylethyl)cyclohexyl](6-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl]- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798537-82-3 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(1-methoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-83-4 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(1-methoxy-1H-benzimidazol-2-yl)amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798537-84-5 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)(6-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798537-85-6 CAPLUS
 CN Acetic acid, [(4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(phenylmethoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)














RN 798537-86-7 CAPLUS
 CN β -Alanine, N-[4-[(5-(cyclopentyloxy)-1-phenyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IT 798537-87-8P 798537-88-9P 798537-89-0P
 798537-90-3P 798537-91-4P 798537-92-5P
 798537-93-6P 798537-94-7P 798537-95-8P
 798537-96-2P 798538-00-8P 798538-04-2P
 798538-03-3P 798538-06-4P 798538-07-5P
 798538-08-6P 798538-09-7P 798538-10-0P
 798538-11-1P 798538-12-2P 798538-13-3P
 798538-14-4P 798538-15-5P 798538-16-6P
 798538-17-7P 798538-18-8P 798538-19-9P
 798538-20-2P 798538-21-3P 798538-22-4P
 798538-23-5P 798538-24-6P 798538-25-7P
 798538-26-8P 798538-27-9P 798538-28-0P
 798538-29-1P 798538-30-4P 798538-31-5P
 798538-32-6P 798538-33-7P 798538-34-8P
 798538-35-9P 798538-36-0P 798538-37-1P
 798538-39-3P 798538-40-6P 798538-41-7P
 798538-42-8P 798538-43-9P 798538-44-0P
 798538-45-1P 798538-90-6P


N-[4-[(trans-4-tert-Butylcyclohexyl)(5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]β-alanine 798547-20-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of benzimidazoles as glucagon receptor antagonists for treating type II diabetes mellitus and their compns. containing them)
 RN 798537-87-8 CAPLUS
 CN Acetic acid, [(4-[(5-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl)amino]hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798537-98-1 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798537-99-2 CAPLUS
 CN Acetic acid, [[4-[[4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798538-00-8 CAPLUS
 CN β -Alanine, N-[4-[[4-(1,1-dimethylethyl)cyclohexyl][1-[(4-methoxyphenyl)methyl]-1H-benzimidazol-2-yl]amino]methyl]benzoyl]- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798538-04-2 CAPLUS
 CN Benzamide, 4-[[6-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-05-3 CAPLUS
 CN β -Alanine, N-[4-[[6-(cyclopentyloxy)-1-phenyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798538-06-4 CAPLUS
 CN Acetic acid, [[4-[[6-(cyclopentyloxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]amino]hydroxy- (9CI) (CA INDEX NAME)




RN 798538-07-5 CAPLUS
 CN Acetic acid, hydroxy[[4-[[1-methyl-6-(2-propenyl)phenyl]amino]methyl]benzoyl]amino]-(9CI) (CA INDEX NAME)




RN 798538-08-6 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl][5-ethoxy-1-methyl-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798538-09-7 CAPLUS
 CN Benzamide, 4-[[5-(cyclobutyloxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798538-10-0 CAPLUS
 CN Benzamide, 4-[[5-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-11-1 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl]- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 798538-12-2 CAPLUS
 CN Benzamide, 4-[[5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-13-3 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-14-4 CAPLUS
 CN β -Alanine, N-[4-[[4-(1,1-dimethylethyl)cyclohexyl](5-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)



L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 798538-17-7 CAPLUS
 CN β -Alanine, N-[4-[[5-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-18-8 CAPLUS
 CN Benzamide, 4-[[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-19-9 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798538-15-5 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclobutylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-16-6 CAPLUS
 CN Benzamide, 4-[[5-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798538-20-2 CAPLUS
 CN Benzamide, 4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-21-3 CAPLUS
 CN β -Alanine, N-[4-[[5-(cyclopentylmethoxy)-1-methyl-1H-benzimidazol-2-yl][4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)





RN 798538-22-4 CAPLUS
 CN Benzamide, 4-[[4-(1,1-dimethylethyl)cyclohexyl][1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl-

L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)


RN 798538-23-5 CAPLUS
CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)



RN 798538-24-6 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)(6-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)

RN 798538-26-8 CAPLUS
CN Benzamide, 4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(1-methylethoxy)-1H-benzimidazol-2-yl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-27-9 CAPLUS
CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(6-ethoxy-1-methyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 798538-28-0 CAPLUS
CN β -Alanine, N-[4-[(6-(cyclopropylmethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-29-1 CAPLUS
CN β -Alanine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)[1-methyl-6-(2-methoxypoxy)-1H-benzimidazol-2-yl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-30-4 CAPLUS
CN Benzamide, 4-[(5-bromo-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)


L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 798538-31-5 CAPLUS
CN β -Alanine, N-[4-[(5-bromo-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-32-6 CAPLUS
CN Glycine, N-[4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-33-7 CAPLUS
CN Butanoic acid, 4-[(4-[(4-(1,1-dimethylethyl)cyclohexyl)(1-ethyl-1H-benzimidazol-2-yl)amino]methyl)benzoyl]amino- (CA INDEX NAME)




RN 798538-34-8 CAPLUS
 CN Benzamide, 4-[(6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-35-9 CAPLUS
 CN β-Alanine, N-[4-[(6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-36-0 CAPLUS
 CN Benzamide, 4-[(6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-37-1 CAPLUS
 CN Benzamide, 4-[(6-(cyclohexyloxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-39-3 CAPLUS
 CN Benzamide, 4-[(6-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-40-6 CAPLUS
 CN β-Alanine, N-[4-[(6-(cyclohexyloxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-41-7 CAPLUS
 CN β-Alanine, N-[4-[(6-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-42-8 CAPLUS
 CN Benzamide, 4-[(6-(cyclohexylmethoxy)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-43-9 CAPLUS
 CN Benzamide, 4-[(1-methyl-1H-benzimidazol-2-yl)[4-(trifluoromethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)



RN 798538-44-0 CAPLUS
 CN Benzamide, 4-[(6-(dichlorophenyl)-1-methyl-5-(pentyloxy)-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]-N-2H-tetrazol-5-yl- (CA INDEX NAME)




RN 798538-45-1 CAPLUS
 CN β-Alanine, N-[4-[(6-(bromo-1,2,3,4-tetrahydro-2-naphthalenyl)-1-methyl-1H-benzimidazol-2-yl)[4-(1,1-dimethylethyl)cyclohexyl]amino]methyl]benzoyl- (CA INDEX NAME)




RN 798538-90-6 CAPLUS
 CN β -Alanine, N-[4-[(trans-4-(1,1-dimethylethyl)cyclohexyl](5-methoxy-1-methyl-1H-benzimidazol-2-yl)amino)methyl]benzoyl]-(CA INDEX NAME)

Relative stereochemistry.



RN 798547-20-3 CAPLUS
 CN Benzamide, 4-[(trans-4-(1,1-dimethylethyl)cyclohexyl)[1-methyl[2-(1-pyrrolidinyl)ethoxy]-1H-benzimidazol-2-yl]amino]methyl]-N-1H-tetrazol-5-yl-(9CI) (CA INDEX NAME)




N-(5,6,7,8-tetrahydro-8-quinoliny)-N-(1H-benzimidazol-2-ylmethyl)amines and analogs as chemokine receptor modulators for treatment of HIV or FIV
 INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Boquiki, David; Wilson, Trevor R.; Crawford, Jason; Meachern, Ernest J.; Atsman, Bernd; Nan, Siquiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria

PATENT ASSIGNEE(S): Anormed Inc., Can.
 SOURCE: PCT Int. Appl., 187 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034745	A1	20020502	WO 2001-US29590	20010917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, T3, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
FW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421796	A1	20020502	CA 2001-2421796	20010917
EP 1317451	A1	20030611	EP 2001-975290	20010917
EP 1317451	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013932	A	20030624	BR 2001-13932	20010917
HU 2003002960	A2	20031229	HU 2003-2960	20010917
HU 2003002960	A3	20070328		
NZ 524651	A	20050826	NZ 2001-524651	20010917
AT 335733	T	20060915	AT 2001-975290	20010917
EP 1752455	A2	20070214	EP 2006-116105	20010917
EP 1752455	A3	20070228		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
ES 2269465	T3	20070401	ES 2001-975290	20010917
RU 2297413	C2	20070420	RU 2003-110579	20010917
AU 2001294628	B2	20070607	AU 2001-294628	20010917
AU 2001094628	A	20020506	AU 2001-94628	20010919
JP 2004512336	T	20040422	JP 2002-537736	20010919
CN 1980916	A	20070613	CN 2001-815802	20010919
US 20030028022	A1	20030206	US 2002-31812	20020328
US 6734191	B2	20040511		
IN 2003KN00182	A	20050311	IN 2003-KN182	20030213
NO 2003001161	A	20030313	NO 2003-1161	20030313
MX 2003PA02327	A	20041101	MX 2003-PA2327	20030313

L7	ANSWER 8 OF 13 CAPLUS	COPYRIGHT 2008 ACS on STN	(Continued)
HK 1059257	A1	20070525	HK 2003-108858
US 20040171638	A1	20040902	US 2004-79386
US 7091217	B2	20060815	20040311
US 20040220207	A1	20041104	US 2004-858910
US 7084155	B2	20060801	20040601
US 20050026942	A1	20050203	US 2004-914663
US 7312234	B2	20071225	20040809
US 20060128750	A1	20060615	US 2006-345987
US 7396840	B2	20080708	20060202
US 20060252795	A1	20061109	US 2006-497038
US 20080090846	A1	20080417	US 2007-956190
PRIORITY APFLN. INFO.:			US 2000-234510P
			P 20000922
			US 2000-234816P
			P 20000922
			US 2000-232891P
			P 20000915
			US 2000-233087P
			P 20000915
			EP 2001-975290
			A3 20010917
			US 2001-957654
			A3 20010917
			US 2001-957682
			A3 20010917
			WO 2001-US29590
			W 20010917
			US 2002-31812
			A1 20020328
			US 2004-799386
			A3 20040311
			US 2004-858910
			A3 20040601
			US 2004-914663
			A1 20040809

OTHER SOURCE(S): MARPAT 136:355235
 GI



I




II

AB Title compds. I [wherein ring A optionally comprises a heteroatom selected from N, O, or S; R1-R3 = non-interfering substituents; R4 and R5 = independently H or (un)substituted alkyl, alkenyl, alkynyl, or acyl; or 2 R5 may form a cyclic amine, optionally containing 1 or more N, O, and/or S; R = independently H or alkyl; X = O or S or (un)substituted C or N; Y = independently halo, OH, SH, SO, SO2, non-N containing organic moiety, (CH2)xCN, (CR2)xNR52, (CR2)xNR(CR2)xNR4, (CR2)xNR(CR2)xNR(CR2)xNR52, (CR2)xCO(CR2)xNR52, (CR2)xCO(CR2)xNR(CR2)xNR4, (CR2)xCO(CR2)xNR(CR2)xNR(CR2)xNR52, (CR2)xNR(CR2)xNR(CR2)xNR52, (CR2)xNR(CR2)xNR(CR2)xNR(CR2)xNR(CR2)xNR52, CH:NZ, (CR2)xZ, NR(CR2)xZ, (CR2)xNR(OH), (CR2)xCONR(OH), or (CR2)xCR:NON; or 2 Y groups may be connected to form a fused ring with Ar; Z = (un)substituted (hetero)aryl; Ar = (hetero)aryl; m = 0-2; n = 0-2; p = 0-4; q = 0-3; x = 0-4; with provisos, and pharmaceutically acceptable salts and pro-drugs thereof] were prepared as modulators of chemokine receptor activities. For example, reductive addition of 3-cyanobenzaldehyde to 8-amino-5,6,7,8-tetrahydroquinoline using sodium triacetoxyborohydride in CH2Cl2 afforded N-(5,6,7,8-tetrahydro-8-quinolinyl)-3-cyanobenzylamine (81%). Alkylation with N-(text-butoxycarbonyl)-2-chloromethylbenzimidazole using N,N-diisopropylethylamine and KI in MeCN (88%), followed by hydrogenation

L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued) in the presence of Raney nickel (79%), gave the tertiary amine II (AMD9679). Compds. of the invention tested for inhibition of HIV-1 NL4.3 or IIIB replication in MT-4 cells exhibited EC50 values of 0.002 μ M/L to 20.0 μ M/L. Thus, I are useful for the treatment of human immunodeficiency virus (HIV) and/or feline immunodeficiency virus (FIV).

IT RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (Chemokine receptor modulator; preparation of N-(tetrahydroquinolinyl)-N-(benzimidazolylmethyl)amines and analogs as chemokine receptor modulators for treatment of HIV or FIV)


RN 422283-95-2 CAPLUS
CN Benzamide, 3-(aminomethyl)-4-[(1H-benzimidazol-2-yl(5,6,7,8-tetrahydro-8-quinolinyl)amino)methyl]-N-hydroxy-, hydrobromide (5:16) (CA INDEX NAME)



●16/5 HBr

IT 421552-01-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intermediate; preparation of N-(tetrahydroquinolinyl)-N-(benzimidazolylmethyl)amines and analogs as chemokine receptor modulators for treatment of HIV or FIV)

RN 421552-01-4 CAPLUS
CN Benzamide, 3-(aminomethyl)-4-[(1H-benzimidazol-2-yl(5,6,7,8-tetrahydro-8-quinolinyl)amino)methyl]-N-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS



L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000-824211 CAPLUS
DOCUMENT NUMBER: 134:4764
TITLE: Preparation of 3-(benzoylamino)propionic acid derivatives as glucagon antagonists/inverse agonists
INVENTOR(S): Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian; Behrens, Carsten; Wagner, Josef; Christensen, Inge Thøger; Lundt, Behrend Frederik; Sideumann, Ulla Grove; Thøgersen, Henning
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 564 pp.
CODEN: PIXXKD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069810	A1	20001123	WO 2000-DK264	20000516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DE, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LS, LT, LV, MA, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, KE, LS, MW, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6503949	B1	20000516	US 2000-572553	20000516
CA 2373892	A1	20001123	CA 2000-2373892	20000516
EP 1183229	A1	20020306	EP 2000-926725	20000516
EP 1183229	B1	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010651	A	20020319	BR 2000-10651	20000516
HU 2002001033	A2	20020729	HU 2002-1033	20000516
HU 2002001033	A3	20030328		
JP 2002544254	T	20021224	JP 2002-618228	20000516
AT 307798	T	20051115	AT 2000-926725	20000516
ES 2250128	T3	20060416	ES 2000-926725	20000516
ZA 2001008560	A	20020613	ZA 2001-8560	20011018
NO 2001005607	A	20020117	NO 2001-5607	20011116
MX 2001PA11757	A	20020604	MX 2001-PA11757	20011116
US 20030220350	A1	20031127	US 2002-233851	20020830
US 6875760	B2	20050405		
US 20050203108	A1	20050915	US 2004-980199	20041103
PRIORITY APPLN. INFO.:			DK 1999-684	A 19990517
			DK 2000-478	A 20000321
			US 1999-134415P	P 19990517
			US 2000-191685P	P 20000323
			US 2000-572553	A3 20000516
			WO 2000-DK264	W 20000516

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
US 2002-233851 A3 20020830
OTHER SOURCE(S): MAPPAT 134:4764

OTHER SOURCE(S): MARPAT 134:4764
GI



The title compds. [I; V = CO2R2, CONNR2R3, CONNR2OR3, etc. (wherein R2, R3 = H, alkyl); A = $(CH_2)_n(CR_8R_9)bNR_7$, $(CR_8R_9)b(CH_2)nNR_7$, $(CR_8R_9)b(CH_2)_n$, etc. (b = 0-1; n = 0-3; R7 = H, alkyl, (cycloalkyl)alkyl; R8, R9 = H, alkyl); Y = CO, SO2, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroatom ring containing 1-2 heteroatoms selected from N, O and S; or AXYZ together = II; R1 = H, alkyl; X = $CO(CR_1R_2r)(CH_2)_sS_0(CR_1R_3R_4r)(CH_2)_s$, $CO_2(CR_1R_4r)(CH_2)_s$, etc. (r = 0-1; s = 0-3; R1, R4 = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopolypropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated disorders and diseases such as hyperglycemia, type 1 diabetes, type 2 diabetes and obesity, were prepared and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.


IT 307984-41-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

USES

(Uses)
(prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)

RN 307984-41-4 CAPLUS
CN β -alanine, N-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl](5,6-dichloro-1H-benzimidazol-2-yl)amino]methyl]benzoyl]-(CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 1977406897 CAPLUS
DOCUMENT NUMBER: 8716897
ORIGINAL REFERENCE NO.: 871119a,1122a
TITLE: N-(Benzimidazol-2-yl)arylcarboxamides as ultraviolet
light absorbers
INVENTOR(S): Merck, Nathaniel
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S. 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4011236	A	19770308	US 1975-580847	19750527
US 3907700	A	19750923	US 1973-320231	19730110
PRIORITY APPLN. INFO.:			US 1968-758601	A2 19680903
			US 1973-320231	A2 19730110

61




AB N-(Benzimidazol-2-yl)arylcaboxamides (I, R1 = aromatic radical with 1-3 nuclei, ring-substituted aromatic radical, aromatic heterocyclic radical; R2 = H, Me, aliphatic or aromatic acyl) were prepared by condensing an anilinobenzimidazol with an aromatic acid halide. These compns. are useful as UV light absorbers in plastics, fibers, sun tan lotions, etc. Thus, p-tert-butylbenzoic acid [98-73-7] was chlorinated with thionyl chloride to give 2-(tert-butylbenzyl)chloride, J7310-98-11, which was condensed


to give p-*tert*-butylbenzoyl chloride [1710-98-1], which was condensed with 2-aminobenzimidazole [934-32-7] to give N-(benzimidazol-2-yl)-4-*tert*-butylbenzamide (I, R₁ = 4-*tert*-butylphenyl, R₂ = H) [25737-69-3].

IT 27111-43-9 57489-96-0P
RL: PREP (Preparation)
(preparation of, for light stabilizers)
RN 27111-43-9 CAPLUS
CN 1,4-Benzenedimedicarboxamide, N1,N4-bis(1H-benzimidazol-2-yl)- (CA INDEX
NBBM1)


L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 57489-96-0 CAPLUS
CN 1,3-Benzenedicarboxamide, N1,N3-bis(1H-benzimidazol-2-yl)- (CA INDEX
NAME)




L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:74508 CAPLUS
 DOCUMENT NUMBER: 86:74508
 ORIGINAL REFERENCE NO.: 86:11805a,11808a
 TITLE: N-(Benzimidazol-2-yl)arylcarboxamides as ultraviolet
 stabilizers
 AUTHOR(S): Grier, Nathaniel
 CORPORATE SOURCE: Merck Sharp Dohme Res. Lab., Merck and Co., Inc.,
 Rahway, NJ, USA
 SOURCE: Journal of Coatings Technology (1976), 48(623), 50-7
 DOCUMENT TYPE: CODEN: JCTEDL; ISSN: 0361-8773
 LANGUAGE: Journal
 English
 GI



AB Nine N-(benzimidazol-2-yl)carboxamides (I, R = aryl, subst. aryl) effectively decreased the color formation in polyurethane coating films when subjected to UV aging. Comparison with 2 com. UV stabilizers showed that N-(benzimidazol-2-yl)-4-tert-butylbenzamide [25737-69-3] gave significant protective action. The UV absorbances and substituent effects

on the spectra were obtained and compared for 19 I derivs.

IT 27111-43-9
 RL: PRP (Properties)
 (UV spectra of)
 RN 27111-43-9 CAPLUS
 CN 1,4-Benzenedicarboxamide, N1,N4-bis(1H-benzimidazol-2-yl) - (CA INDEX
 NAME)




IT 57489-96-0
 RL: USES (Uses)
 (light stabilizers, for coatings)
 RN 57489-96-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N1,N3-bis(1H-benzimidazol-2-yl) - (CA INDEX

L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1976:4959 CAPLUS
 DOCUMENT NUMBER: 84:4959
 ORIGINAL REFERENCE NO.: 84:841a,844a
 TITLE: Control of uv deterioration by incorporation of N-(benzimidazol-2-yl) arylcarboxamides into a uv sensitive substance
 INVENTOR(S): Grier, Nathaniel
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 14 pp.
 CODEN: USXKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3907700	A	19750923	US 1973-320231	19730102
NL 6913261	A	19700311	NL 1969-12261	19690829
GB 1287955	A	19720906	GB 1969-39264	19690904
GB 1287954	A	19720906	GB 1969-43800	19690904
BE 738534	A	19700309	BE 1969-738534	19690908
FR 2017676	A5	19700522	FR 1969-30666	19690909
CH 555387	A	19741031	CH 1969-13630	19690909
US 4011236	A	19770308	US 1975-580847	19750527
PRIORITY APFLN. INFO.:		US 1968-758601	A2 19680909	
		US 1973-320231	A3 19730102	

GI For diagram(s), see printed CA Issue.
 AB Amides I (R = C6H4Me3-4, 4-thiazolyl, 2-thienyl, 5-tert-butyl-2-furyl, C6H4CO2Bu-2, C6H4CO2Et-4, 4- or 3-(2-benzimidazolylaminocarbonyl)phenyl, N-(2-benzimidazolyl)phthalimid-4-yl, R1 = H; R = Ph, R1 = 4-Me; R = 2-furyl; R1 = 5-Cl) were prepared by acylating the 2-aminoimidazoles. I are uv absorbers for plastics and sunscreens.
 IT 27111-43-9; 57489-96-0P
 RL: SFP (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 27111-43-9 CAPLUS
 CN 1,4-Benzenedicarboxamide, N1,N4-bis(1H-benzimidazol-2-yl) - (CA INDEX
 NAME)




RN 57489-96-0 CAPLUS
 CN 1,3-Benzenedicarboxamide, N1,N3-bis(1H-benzimidazol-2-yl) - (CA INDEX
 NAME)

L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 NAME)



L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L7 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:132730 CAPLUS
 DOCUMENT NUMBER: 72:132730
 ORIGINAL REFERENCE NO.: 72:23766h,23767a
 TITLE: Ultraviolet-absorbing
 N-(2-benzimidazolyl)carboxamides
 INVENTOR(S): Gier, Nathaniel
 PATENT ASSIGNEE(S): Merck and Co., Inc.
 SOURCE: Ger. Offen., 50 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1945452	----	19700319	DE 1969-1945452	19690908
FR 2017676	FR			
GB 1287954	GB			
GB 1287955	GB			

PRIORITY APPLN. INFO.:

US 19680909

GI For diagram(s), see printed CA Issue.

AB The title compds., absorbing at 300-500 nm, were prepared. Thus, 15.7 g *p*-tert-BuC₆H₄COCl, b2.2 100° formed from the acid and SOCl₂, and 10.7 g 2-aminobenzimidazole (I) in 100 ml pyridine were heated 1.5 hr to give 22.5 g II (R = *p*-tert-BuC₆H₄, R1 = H), m. 246-8°. Similarly prepared were II (R, R1, and m.p. given): 4-thiazolyl, H, 294-6°; 2-benzofuryl, H, 293-4°; 3-pyridyl, H, -2-furyl, Cl, 250-1°; β -(2-furyl)vinyl, H, 250-1°; 5-tert-butyl-2-furyl, H, 257.5-9°; 5-phenyl-2-furyl, H, 224-5.5°; and III (Y = *m*-phenylene), m. >320°; III (Y = *p*-phenylene), m. >340°; IV (R2 = H) (IVa), m. 266-8°, and IV (R2 = 2-benzimidazolylaminocarbonyl), m. 352-3°. IVa (4 g) in 200 ml BuOH was heated 35 min at 115° to give 2.5 g II (R = o-BuC₆H₄, R1 = H), m. 187°. 2-Thienyl chloride (0.04 mole) in 15 ml HCONMe₂ was added to 0.02 mole H₂NCSMe:NH₂SO₄ and 0.04 mole Et₃N in 50 ml HCONMe₂ at 0° and stirred 2 hr at room temperature to give V, m. 166-7°. V (0.01 mole) and 1.08 g o-phenylenediamine in 50 ml EtOH was refluxed 5 hr to give II (R = 2-thienyl, R1 = H), m. 303-5°. They can be incorporated into plastics to protect them against the discoloration, impairment of tensile strength, or brittleness. They can be added directly to dyes, plasticizers, antimicrobial agents, insect repellents, suntan lotions, or skin creams and can be used for textiles, in varnishes for wood, masonry, and metals, in plastic packages for foods, and in hair creams.

IT 27111-42-8P 27111-43-9P


RL: SRN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 27111-42-8 CAPLUS

CN 1,2-Benzeneddicarboxamide, N1,N2-bis(1H-benzimidazol-2-yl) - (CA INDEX NAME)

L7 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27111-43-9 CAPLUS
 CN 1,4-Benzeneddicarboxamide, N1,N2-bis(1H-benzimidazol-2-yl) - (CA INDEX NAME)



10/556,230 12/21/2008

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION

FULL ESTIMATED COST

79.01	440.08
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

-10.40	-10.40
--------	--------

STN INTERNATIONAL LOGOFF AT 18:55:12 ON 21 DEC 2008